<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76988</article-id><article-id pub-id-type="doi">10.7554/eLife.76988</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Global variation in force-of-infection trends for human T<italic>aenia solium</italic> taeniasis/cysticercosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-266646"><name><surname>Dixon</surname><given-names>Matthew A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1710-6237</contrib-id><email>m.dixon15@imperial.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54085"><name><surname>Winskill</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269388"><name><surname>Harrison</surname><given-names>Wendy E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-178240"><name><surname>Whittaker</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-269389"><name><surname>Schmidt</surname><given-names>Veronika</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269390"><name><surname>Flórez Sánchez</surname><given-names>Astrid Carolina</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-262220"><name><surname>Cucunuba</surname><given-names>Zulma M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8165-3198</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269392"><name><surname>Edia-Asuke</surname><given-names>Agnes U</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-269393"><name><surname>Walker</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-4074"><name><surname>Basáñez</surname><given-names>María-Gloria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research (LCNTDR), Faculty of Medicine, School of Public Health, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology Faculty of Medicine, School of Public Health, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>SCI Foundation, Edinburgh House</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02kkvpp62</institution-id><institution>Department of Neurology, Center for Global Health, Technical University Munich (TUM)</institution></institution-wrap><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xtthb56</institution-id><institution>Centre for Global Health, Institute of Health and Society, University of Oslo</institution></institution-wrap><addr-line><named-content content-type="city">Oslo</named-content></addr-line><country>Norway</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yxg7206</institution-id><institution>Grupo de Parasitología, Instituto Nacional de Salud</institution></institution-wrap><addr-line><named-content content-type="city">Bogotá</named-content></addr-line><country>Colombia</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/019apvn83</institution-id><institution>Ahmadu Bello University</institution></institution-wrap><addr-line><named-content content-type="city">Zaria</named-content></addr-line><country>Nigeria</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01wka8n18</institution-id><institution>Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research (LCNTDR), Royal Veterinary College</institution></institution-wrap><addr-line><named-content content-type="city">Hatfield</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ferreira</surname><given-names>Marcelo U</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>University of São Paulo</institution></institution-wrap><country>Brazil</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>University of New South Wales</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e76988</elocation-id><history><date date-type="received" iso-8601-date="2022-01-11"><day>11</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-07"><day>07</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-02-11"><day>11</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.02.11.22270710"/></event></pub-history><permissions><copyright-statement>© 2022, Dixon et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Dixon et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76988-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-76988-figures-v1.pdf"/><abstract><p>Infection by <italic>Taenia solium</italic> poses a major burden across endemic countries. The World Health Organization (WHO) 2021–2030 Neglected Tropical Diseases roadmap has proposed that 30% of endemic countries achieve intensified <italic>T. solium</italic> control in hyperendemic areas by 2030. Understanding geographical variation in age-prevalence profiles and force-of-infection (FoI) estimates will inform intervention designs across settings. Human taeniasis (HTT) and human cysticercosis (HCC) age-prevalence data from 16 studies in Latin America, Africa, and Asia were extracted through a systematic review. Catalytic models, incorporating diagnostic performance uncertainty, were fitted to the data using Bayesian methods, to estimate rates of antibody (Ab)-seroconversion, infection acquisition and Ab-seroreversion or infection loss. HCC FoI and Ab-seroreversion rates were also estimated across 23 departments in Colombia from 28,100 individuals. Across settings, there was extensive variation in all-ages seroprevalence. Evidence for Ab-seroreversion or infection loss was found in most settings for both HTT and HCC and for HCC Ab-seroreversion in Colombia. The average duration until humans became Ab-seropositive/infected decreased as all-age (sero)prevalence increased. There was no clear relationship between the average duration humans remain Ab-seropositive and all-age seroprevalence. Marked geographical heterogeneity in <italic>T. solium</italic> transmission rates indicate the need for setting-specific intervention strategies to achieve the WHO goals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>taenia solium</kwd><kwd>one health</kwd><kwd>modelling</kwd><kwd>neglected tropical diseases</kwd><kwd>statistics</kwd><kwd>zoonotic infections</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/R015600/1</award-id><principal-award-recipient><name><surname>Dixon</surname><given-names>Matthew A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Marked geographical heterogeneity in global <italic>Taenia solium</italic> transmission rates indicate the need for setting-specific intervention strategies to achieve the WHO NTD 2021-2030 roadmap milestones for <italic>T. solium</italic>.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The zoonotic cestode <italic>Taenia solium</italic> poses a substantial public health and economic challenge. Globally, <italic>T. solium</italic> is ranked as the foodborne parasitic infection contributing the highest number of disability-adjusted life-years (DALYs), an estimated 2.78 million DALYs in 2010 (<xref ref-type="bibr" rid="bib38">Havelaar et al., 2015</xref>). Control and elimination of <italic>T. solium</italic> requires a One Health approach (<xref ref-type="bibr" rid="bib69">Thomas et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Braae et al., 2019</xref>) due to its complex multi-host life-cycle, involving infection with larval-stage cysticerci in the intermediate pig host (porcine cysticercosis, or PCC), infective stages (eggs) in the environment, and taeniasis (infection with the adult worm) in the definitive human host (human taeniasis, or HTT). When humans ingest <italic>T. solium</italic> eggs, establishment of cysticerci (human cysticercosis, or HCC) in the central nervous system results in neurocysticercosis. Neurocysticercosis is responsible for the major health burden associated with <italic>T. solium</italic>, causing approximately one third of epilepsy/seizure disorders in endemic settings (<xref ref-type="bibr" rid="bib34">Gripper and Welburn, 2017</xref>).</p><p>Current interventions target PCC through mass treatment of pigs with oxfendazole and their vaccination with TSOL18, and HTT through mass treatment of humans with praziquantel or niclosamide. These control strategies have proven efficacious in field studies (<xref ref-type="bibr" rid="bib10">de Coster et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Dixon et al., 2021</xref>), but to date no large-scale interventions have been rolled out as part of national Neglected Tropical Disease (NTD) programmes, and therefore their impact alone or in combination in different epidemiological settings remains poorly understood and/or modelled (<xref ref-type="bibr" rid="bib9">CystiTeam Group for Epidemiology and Modelling of Taenia solium Taeniasis/Cysticercosis, 2019</xref>). The milestones proposed in the new World Health Organization (WHO) NTD 2021–2030 roadmap (<xref ref-type="bibr" rid="bib38">Havelaar et al., 2015</xref>; <xref ref-type="bibr" rid="bib75">World Health Organization, 2020</xref>) focus on achieving intensified control in hyperendemic areas of 17 (27%) endemic countries. However, endemicity levels for <italic>T. solium</italic> have not been defined in terms of infection indicators and there exist limited data on the geographical distribution of <italic>T. solium</italic> prevalence at national scales. For other NTDs, pre-intervention levels of endemicity (according to infection prevalence, intensity, incidence or morbi-mortality) determine the magnitude, duration and likely success of control efforts (<xref ref-type="bibr" rid="bib59">NTD Modelling Consortium Onchocerciasis Group, 2019</xref>). Therefore, successful <italic>T. solium</italic> intervention strategies will require tailoring to local epidemiological and socio-economic conditions that determine the intensity of transmission and will likely be informed by age- and/or sex-dependent contact rates and mixing patterns in endemic settings (<xref ref-type="bibr" rid="bib16">Dixon et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">CystiTeam Group for Epidemiology and Modelling of Taenia solium Taeniasis/Cysticercosis, 2019</xref>; <xref ref-type="bibr" rid="bib73">Welburn et al., 2015</xref>).</p><p>Global patterns in transmission rates have recently been explored for PCC by assessing the force-of-infection (FoI; the per-capita rate of infection acquisition) according to proposed endemicity levels (overall (sero)prevalence) and geography (<xref ref-type="bibr" rid="bib15">Dixon et al., 2020</xref>). Estimates of antibody (Ab) and antigen (Ag) seroconversion (and seroreversion rates) for HCC have also been estimated from a small number of longitudinal surveys in Burkina Faso (<xref ref-type="bibr" rid="bib11">Dermauw et al., 2018</xref>), Peru (<xref ref-type="bibr" rid="bib28">Garcia et al., 2001</xref>), Ecuador (<xref ref-type="bibr" rid="bib7">Coral-Almeida et al., 2014</xref>), and Zambia (<xref ref-type="bibr" rid="bib54">Mwape et al., 2013</xref>), demonstrating substantial geographic variation.</p><p>Age-prevalence profiles are not only useful for estimating FoI and (sero)reversion rates, but also to provide insight into processes driving epidemiological dynamics, such as immunological responses or heterogeneity in exposure which may explain abrupt changes in HCC seropositivity in older individuals or distinct prevalence peaks in younger ages for HTT prevalence, as observed in the Democratic Republic of the Congo (DRC) (<xref ref-type="bibr" rid="bib42">Kanobana et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Madinga et al., 2017</xref>). Specific age-prevalence profiles may also provide insight into whether age-targeted interventions may be appropriate in certain settings. This study, therefore, and for the first time systematically collates and reviews all HTT and HCC age-(sero)prevalence data available from the literature and from collaborators, and uses simple and reversible catalytic models to estimate the FoI and Ab-seroreversion/infection loss rates from cross-sectional surveys. The results improve our understanding of global variation in the epidemiology of <italic>T. solium</italic> and provide estimates of transmission rates, crucial for guiding the design of interventions. In addition, a country profile of FoI estimates is presented at the sub-national level for Colombia to exemplify how detailed FoI analyses can help understand local epidemiological patterns.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Systematic review and study selection</title><p>After title, abstract and full-text eligibility screening of 236 studies initially identified (01/11/2014 to 02/10/2019), and 11 studies included in the <xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref> literature review, a total of 16 studies were included in the analysis (PRISMA flowchart; <xref ref-type="fig" rid="fig1">Figure 1</xref>), originating from South America (n=4), Africa (n=8) and Asia (n=4) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and split by n=4 HTT and n=15 HCC surveys (full details in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Published articles on age-(sero)prevalence profiles identified in the updated literature search using a <xref ref-type="bibr" rid="bib50">Moher et al., 2015</xref> search.</title><p>Additional studies identified from the <xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref> review also shown. LILAC: Latin American and Caribbean Health Sciences Literature; AJOL: African Journals Online.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Geographical distribution of studies with human taeniasis (HTT) and human cysticercosis (HCC) age-(sero) prevalence data included in the final analysis (n=16) by diagnostic target.</title><p>There are 19 indicators in total, as three studies provided more than one indicator (<xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>; <xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Total sample sizes were 6,653 individuals (range 576–4599; with individual age range of &lt;1–96 years) across HTT surveys, which included three copro-Ag-based surveys and one Ab-based survey; 34,124 (125–29,360; cross-study age range of &lt;1–95 years) across HCC-Ab surveys, and 12,934 (708–4993; cross-study age range of &lt;1–96 years) across HCC-Ag surveys. Observed (sero)prevalence ranged from 4.5% to 23.4% (95% confidence interval (CI) range: 3.0–24.6%) for HTT surveys, 0.5–38.7% (0.1–41.6%) across HCC-Ab surveys, and 0.7–21.7% (0.5–24.5%) across HCC-Ag surveys.</p><p>Catalytic models (<xref ref-type="fig" rid="fig2">Figure 2</xref>; full details in Materials and methods) were fitted to the thus extracted (sero)prevalence data using a Bayesian framework that integrates uncertainty in diagnostic sensitivity and specificity from prior (published) information (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The FoI parameters of acquisition (<italic>λ</italic>) and reversion/loss (<italic>ρ</italic>) (for antibody datasets, a marker of exposure: <italic>λ<sub>sero</sub></italic> and <italic>ρ<sub>sero</sub></italic>; for antigen datasets, a marker of active infection: <italic>λ<sub>inf</sub></italic> and <italic>ρ<sub>inf</sub></italic>) were estimated for each dataset. The deviance information criterion (DIC) (<xref ref-type="bibr" rid="bib67">Spiegelhalter et al., 2002</xref>) was used to compare individually- and jointly-fitted catalytic models.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Simple and reversible catalytic model structure and equations fitted to data on the age (a)-specific (sero)prevalence (<italic>p</italic>(<italic>a</italic>)) data, where <italic>λ</italic> is the force-of-infection (rate of antibody (Ab)-seroconversion or infection acquisition) and ρ the rate of Ab-seroreversion or infection loss.</title><p>The general mathematical form of the catalytic models (<xref ref-type="disp-formula" rid="equ1">equations 1a</xref> to 1d) fitted to the human taeniasis (HTT)/human cysticercosis (HCC) Ab, HCC Ag and HTT copro-Ag prevalence datasets to estimate the prevalence (<italic>p</italic>) at human age (<italic>a</italic>). The saturating (sero)prevalence is given by λ/(λ + ρ) which for the simple model is 100%, if the humans lived sufficiently long. The accompanying tables provide information on the definitions of the catalytic model parameters depending on the diagnostic method. Presence of adult tapeworm excretory-secretory products indicative of active or past HTT infection, as outlined by <xref ref-type="bibr" rid="bib46">Lightowlers et al., 2016a</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig2-v1.tif"/></fig><p>We defined hyperendemic transmission settings as those with all-age <italic>observed</italic> HTT (sero)prevalence of ≥3% and all-age <italic>observed</italic> HCC (sero)prevalence of ≥6%. Studies with (sero)prevalence values below these were defined as endemic transmission settings. These putative endemicity definitions were defined following a literature review of studies referring to ‘hyper’ or ‘highly’ endemic settings (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> with additional explanatory text in Appendix 1).</p></sec><sec id="s2-2"><title>Global human taeniasis (HTT) copro-antigen and antibody seroprevalence</title><p><xref ref-type="table" rid="table1">Table 1</xref> compares models fitted either including (reversible model) or excluding (simple model) HTT infection loss (when fitted to copro-Ag ELISA using the <xref ref-type="bibr" rid="bib1">Allan et al., 1990</xref> protocol datasets, except in <xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref> where a protocol is not specified) or Ab-seroreversion. For the copro-Ag ELISA datasets (to which models were jointly fitted to yield a single sensitivity and specificity posterior), DIC scores were similar (within one unit) between models with and without infection loss (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig3">Figure 3a</xref>), indicating limited information to differentiate between model fits.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The relationship between human taeniasis copro-antigen (Copro-Ag) and antibody (sero)prevalence and human age (in years) for each dataset.</title><p>Human taeniasis (HTT) infection acquisition (simple) or acquisition with infection loss (reversible) catalytic models jointly fitted to multiple datasets (where single diagnostic sensitivity and specificity values were estimated; dataset-specific λ and ρ estimates were obtained) in <bold>a</bold>; HTT antibody (Ab)-seroconversion (simple) or Ab-seroconversion with Ab-seroreversion to a single dataset in <bold>b</bold>. 95% confidence intervals associated with observed (sero)prevalence point estimates are also presented. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the parameter posterior distributions used to construct predicted (all age) (sero)prevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-fitting model selected by deviance information criterion (DIC); both models presented if difference between DIC &lt; 2 (both models have similar support based on the data); a difference &gt; 10 units indicates that the models are significantly different and therefore only superior fitting model (lowest DIC) is presented. The non-zero predicted (sero)prevalence at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-(sero)prevalence data-points are calculated by the Clopper-Pearson exact method.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig3-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Parameter posterior estimates for the best-fit catalytic models fitted to human taeniasis age-(sero)prevalence datasets (ordered by decreasing all-age (sero)prevalence).</title><p>Parameters estimated from antibody-based datasets measure exposure dynamics, with seroconversion λ<italic><sub>sero</sub></italic> and seroreversion ρ<italic><sub>sero</sub></italic> rates. Parameters estimated from antigen-based datasets measure active infection dynamics, with infection acquisition λ<italic><sub>inf</sub></italic> and infection loss ρ<italic><sub>inf</sub></italic> rates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Dataset; Country</th><th align="left" valign="bottom">All-age observed (sero)- prevalence (%)(95% CI)<xref ref-type="table-fn" rid="table1fn1">*</xref></th><th align="left" valign="bottom">Catalytic model</th><th align="left" valign="bottom">Diagnostic sensitivity(95% BCI)</th><th align="left" valign="bottom">Diagnostic specificity(95% BCI)</th><th align="left" valign="bottom"><italic>λ</italic>=infection acquisition (<italic>λ<sub>inf</sub>)</italic> or Ab-seroconversion (<italic>λ<sub>sero</sub>)</italic> rate, year<sup>–1</sup>(95% BCI)<xref ref-type="table-fn" rid="table1fn2">†</xref></th><th align="left" valign="bottom"><italic>ρ</italic>=infection loss <italic>(ρ<sub>inf</sub>)</italic> orAb-seroreversion <italic>(ρ<sub>sero</sub>)</italic> rate, year<sup>–1</sup>(95% BCI)<xref ref-type="table-fn" rid="table1fn2">†</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="7">Models jointly fitted to multiple datasets (Copro-Ag ELISA) <xref ref-type="table-fn" rid="table1fn3">‡</xref></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>; Zambia<break/>Antigen <xref ref-type="table-fn" rid="table1fn4">§</xref></td><td align="char" char="." valign="bottom">6.32<break/>(4.65–8.37)</td><td align="left" valign="bottom" rowspan="2">Reversible <xref ref-type="table-fn" rid="table1fn5">¶</xref></td><td align="char" char="." valign="bottom" rowspan="2">0.824<break/>(0.533–0.972)</td><td align="left" valign="bottom" rowspan="2">0.959<break/>(0.941–0.976)</td><td align="left" valign="bottom">0.021<break/>(0.0038–0.062)</td><td align="left" valign="bottom">0.768<break/>(0.362–0.991)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>;<break/>Brazil<break/>Antigen<xref ref-type="table-fn" rid="table1fn6">**</xref></td><td align="char" char="." valign="bottom">4.51<break/>(2.97–6.54)</td><td align="left" valign="bottom">0.0096<break/>(0.00072–0.032)</td><td align="left" valign="bottom">0.731<break/>(0.379–0.978)</td></tr><tr><td align="left" valign="bottom" colspan="7">Models independently fitted to single datasets (rES33-immunoblot)<xref ref-type="table-fn" rid="table1fn7">††</xref></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref>;<break/>Lao PDR<break/>Antibody</td><td align="char" char="." valign="bottom">2.49<break/>(1.51–3.87)</td><td align="left" valign="bottom">Simple <xref ref-type="table-fn" rid="table1fn8">‡ ‡</xref></td><td align="char" char="." valign="bottom">0.982<break/>(0.959–0.996)</td><td align="left" valign="bottom">0.992<break/>(0.978–0.999)</td><td align="left" valign="bottom">0.00044<break/>(0.000103–0.00082)</td><td align="left" valign="bottom">NA</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Observed (sero)prevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.</p></fn><fn id="table1fn2"><label>†</label><p>Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).</p></fn><fn id="table1fn3"><label>‡</label><p>Diagnostic sensitivity and specificity jointly fitted for the Copro-Ag ELISA (<xref ref-type="bibr" rid="bib1">Allan et al., 1990</xref>) across age-prevalence datasets; model parameters interpreted in terms of representing infection, with infection acquisition (<italic>λ<sub>inf</sub></italic>) and infection loss (<italic>ρ<sub>inf</sub></italic>) rates.</p></fn><fn id="table1fn4"><label>§</label><p>Based on the <xref ref-type="bibr" rid="bib1">Allan et al., 1990</xref> protocol.</p></fn><fn id="table1fn5"><label>¶</label><p>Best-fitting model determined by DIC (models jointly fitted to multiple dataset).</p></fn><fn id="table1fn6"><label>**</label><p>no protocol specified (assumed to be the <xref ref-type="bibr" rid="bib1">Allan et al., 1990</xref> protocol). NA = Not applicable;, PDR: People’s Democratic Republic.</p></fn><fn id="table1fn7"><label>††</label><p>Model parameters for antibody-based age-seroprevalence data (based on the rES33-immunoblot <xref ref-type="bibr" rid="bib74">Wilkins et al., 1999</xref>), interpreted in terms of exposure, with Ab-seroconversion (<italic>λ</italic><sub>sero</sub>) and Ab-seroreversion (<italic>ρ</italic><sub>sero</sub>) rates.</p></fn><fn id="table1fn8"><label>‡ ‡</label><p>Best-fitting model determined by DIC (models independently fitted to single dataset).</p></fn></table-wrap-foot></table-wrap><p>The copro-Ag ELISA datasets (<xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>; <xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>) were found in hyperendemic settings (all-age HTT (sero)prevalence ≥3%) in Zambia (6.3%) (<xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>) and Brazil (4.5%) (<xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>). For the models independently fitted to the single dataset in Lao People’s Democratic Republic (Lao PDR) (<xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref>) using the rES33-immunoblot (<xref ref-type="bibr" rid="bib74">Wilkins et al., 1999</xref>) and found in an endemic setting (all-age HTT antibody seroprevalence of 2.5%), there was also limited information to differentiate between model fits, with DIC scores similar (within one unit) between the model with and without Ab-seroconversion (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig3">Figure 3b</xref>). The FoI (<italic>λ<sub>sero</sub></italic>) for the best-fit model to the rES33-immunoblot antibody dataset in Lao PDR (<xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref>), suggested a very low HTT Ab-seroconversion rate of 0.00046 year<sup>–1</sup> (all model fits and DIC scores in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The <xref ref-type="bibr" rid="bib49">Madinga et al., 2017</xref> dataset in the DRC was omitted from the models jointly fitted across copro-Ag ELISA datasets, due to difficulty fitting catalytic models to such a distinct age-prevalence profile with a marked peak in early ages (see Discussion).</p></sec><sec id="s2-3"><title>Global human cysticercosis (HCC) antibody seroprevalence</title><p>HCC Ab-seroconversion with Ab-seroreversion (reversible model) provided an improved joint fit to the multiple datasets based on the antibody lentil lectin-purified glycoprotein enzyme-linked immunoelectrotransfer blot (LLGP-EITB) assay (<xref ref-type="bibr" rid="bib70">Tsang et al., 1989</xref>; <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig4">Figure 4a</xref>). These fits were found in the proposed hyperendemic settings (≥6% HCC seroprevalence; with all-age seroprevalence from 12.7% to 24.7%) in Peru (<xref ref-type="bibr" rid="bib45">Lescano et al., 2009</xref>; <xref ref-type="bibr" rid="bib51">Moro et al., 2003</xref>), India (<xref ref-type="bibr" rid="bib40">Jayaraman et al., 2011</xref>), and Bali (<xref ref-type="bibr" rid="bib68">Theis et al., 1994</xref>), and an endemic setting in Brazil (1.6%) (<xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>). For the models jointly fitted to multiple datasets based on the IgG Ab-ELISA (<xref ref-type="bibr" rid="bib12">DiagAutom, 2016</xref>) hyperendemic setting: all-age seroprevalence from 9.6% to 14.5% in Nigeria (<xref ref-type="bibr" rid="bib19">Edia-Asuke et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Weka et al., 2013</xref>), and the models independently fitted to the single dataset from Lao PDR (endemic setting: 3.0% all-age seroprevalence) (<xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref>) based on the rT24H-immunoblot (<xref ref-type="bibr" rid="bib36">Hancock et al., 2006</xref>), the (simple) model without Ab-seroreversion provided an improved fit (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig4">Figure 4b and c</xref>). <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> presents all model fits and DIC scores.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The relationship between human cysticercosis antibody (Ab)-seroprevalence and human age (in years) for each dataset.</title><p>Ab-seroconversion (simple) or Ab-seroconversion with Ab-seroreversion (reversible) catalytic models (<bold>a &amp; b</bold>) jointly fitted to multiple datasets (single diagnostic sensitivity and specificity values estimated; dataset-specific <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> estimates obtained) and (<bold>c</bold>) models independently fitted to a single dataset, including 95% confidence intervals associated with observed Ab-seroprevalence point estimates. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the estimated parameter posterior distributions used to construct predicted (all age) seroprevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-fitting models were selected using the deviance information criterion (DIC); both models presented if difference between DIC &lt; 2 (both models have similar support based on the data); a difference &gt; 10 units indicates that the models are significantly different and therefore only superior fitting model (lowest DIC) is presented. The non-zero predicted seroprevalence at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CIs) for age-seroprevalence data-points are calculated by the Clopper-Pearson exact method.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig4-v1.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Antibody seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antibody) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).</title><p>Antibody seroconversion and seroreversion rates represent markers of exposure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Dataset;Country</th><th align="left" valign="bottom">All-age observed sero- prevalence (%)(95% CI)<xref ref-type="table-fn" rid="table2fn1">*</xref></th><th align="left" valign="bottom">Catalytic model</th><th align="left" valign="bottom">Diagnostic sensitivity(95% BCI)</th><th align="left" valign="bottom">Diagnostic specificity(95% BCI)</th><th align="left" valign="bottom"><italic>λ<sub>sero</sub></italic>sero seroconversion rate, year<sup>–1</sup>(95% BCI)<xref ref-type="table-fn" rid="table2fn2">†</xref></th><th align="left" valign="bottom"><italic>ρ<sub>sero</sub></italic>sero seroreversion rate, year<sup>–1</sup>(95% BCI)<xref ref-type="table-fn" rid="table2fn2">†</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="7">Models jointly fitted to multiple datasets (LLGP-EITB assay) <xref ref-type="table-fn" rid="table2fn3">‡</xref></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Lescano et al., 2009</xref>;<break/>Peru</td><td align="left" valign="bottom">24.66<break/>(21.59–27.94)</td><td align="left" valign="bottom" rowspan="5">Reversible<xref ref-type="table-fn" rid="table2fn4">§</xref></td><td align="left" valign="bottom" rowspan="5">0.976<break/>(0.937–0.994)</td><td align="left" valign="bottom" rowspan="5">0.980<break/>(0.967–0.988)</td><td align="left" valign="bottom">0.12<break/>(0.067–0.19)</td><td align="left" valign="bottom">0.38<break/>(0.21–0.62)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib51">Moro et al., 2003</xref>;<break/>Peru</td><td align="left" valign="bottom">20.82<break/>(16.48–25.71)</td><td align="left" valign="bottom">0.11<break/>(0.0504–0.21)</td><td align="left" valign="bottom">0.501<break/>(0.23–0.92)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Jayaraman et al., 2011</xref>;<break/>India</td><td align="left" valign="bottom">15.81<break/>(13.66–18.16)</td><td align="left" valign="bottom">0.019<break/>(0.0095–0.093)</td><td align="left" valign="bottom">0.105<break/>(0.042–0.56)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib68">Theis et al., 1994</xref>;<break/>Bali</td><td align="left" valign="bottom">12.68<break/>(10.48–15.16)</td><td align="left" valign="bottom">0.024<break/>(0.011–0.052)</td><td align="left" valign="bottom">0.16<break/>(0.054–0.38)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>;<break/>Brazil</td><td align="left" valign="bottom">1.64<break/>(0.82–2.93)</td><td align="left" valign="bottom">0.000086 (0.000011–0.00066)</td><td align="left" valign="bottom">0.43<break/>(0.098–1.49)</td></tr><tr><td align="left" valign="bottom" colspan="7">Models jointly fitted to multiple datasets (IgG Ab-ELISA) <xref ref-type="table-fn" rid="table2fn5">¶</xref></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Edia-Asuke et al., 2015</xref>;<break/>Nigeria</td><td align="left" valign="bottom">14.53<break/>(10.72–19.06)</td><td align="left" valign="bottom" rowspan="2">Simple<xref ref-type="table-fn" rid="table2fn4">§</xref></td><td align="left" valign="bottom" rowspan="2">0.872<break/>(0.784–0.942)</td><td align="left" valign="bottom" rowspan="2">0.974<break/>(0.916–0.998)</td><td align="left" valign="bottom">0.0044<break/>(0.0018–0.0064)</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Weka et al., 2013</xref>;<break/>Nigeria</td><td align="left" valign="bottom">9.60<break/>(5.06–16.17)</td><td align="left" valign="bottom">0.0023<break/>(0.00053–0.0046)</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom" colspan="7">Models independently fitted to an single dataset (rT24H-immunoblot)<xref ref-type="table-fn" rid="table2fn6">**</xref></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref>;<break/>Lao PDR</td><td align="left" valign="bottom">2.96<break/>(1.86–4.44)</td><td align="left" valign="bottom">Simple<xref ref-type="table-fn" rid="table2fn7">††</xref></td><td align="left" valign="bottom">0.964<break/>(0.914–0.988)</td><td align="left" valign="bottom">0.986<break/>(0.969–0.997)</td><td align="left" valign="bottom">0.00044<break/>(0.000049–0.00090)</td><td align="left" valign="bottom">NA</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.</p></fn><fn id="table2fn2"><label>†</label><p>Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI). NA = Not applicable; PDR: People’s Democratic Republic.</p></fn><fn id="table2fn3"><label>‡</label><p>Diagnostic sensitivity and specificity jointly fitted for the LLGP-EITB assay (<xref ref-type="bibr" rid="bib70">Tsang et al., 1989</xref>) across datasets.</p></fn><fn id="table2fn4"><label>§</label><p>Best-fitting model determined by DIC (models jointly fitted to multiple datasets).</p></fn><fn id="table2fn5"><label>¶</label><p>Diagnostic sensitivity and specificity jointly fitted for the IgG Ab-ELISA (DiagnosticAutomation/CortezDiagnostic, Inc, 2016) across datasets.</p></fn><fn id="table2fn6"><label>**</label><p>Best-fitting model determined by DIC (models independently fitted to a single dataset).</p></fn><fn id="table2fn7"><label>††</label><p>Based on the rT24H-immunoblot (<xref ref-type="bibr" rid="bib36">Hancock et al., 2006</xref>).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Global human cysticercosis (HCC) antigen seroprevalence</title><p>HCC infection acquisition with infection loss (reversible model) provided an improved fit for models fitted jointly to multiple datasets based on B158/B60 Ag-ELISA (<xref ref-type="bibr" rid="bib5">Brandt et al., 1992</xref>; <xref ref-type="bibr" rid="bib18">Dorny et al., 2000</xref>; <xref ref-type="table" rid="table3">Table 3</xref> and <xref ref-type="fig" rid="fig5">Figure 5a</xref>), found in one hyperendemic setting (all-age HCC seroprevalence of 21.7%) in the DRC (<xref ref-type="bibr" rid="bib42">Kanobana et al., 2011</xref>), and endemic settings in Zambia (<xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>), Burkina Faso (<xref ref-type="bibr" rid="bib64">Sahlu et al., 2019</xref>), Lao PDR (<xref ref-type="bibr" rid="bib6">Conlan et al., 2012</xref>) and Cameroon (<xref ref-type="bibr" rid="bib57">Nguekam et al., 2003</xref>; all-age HCC seroprevalences from 0.7% to 5.8%). For models fitted to the single dataset from a hyperendemic setting in Kenya (6.61%) (<xref ref-type="bibr" rid="bib71">Wardrop et al., 2015</xref>), using the HP10 Ag-ELISA (<xref ref-type="bibr" rid="bib37">Harrison et al., 1989</xref>), the (simple) model without infection loss provided an improved fit (<xref ref-type="table" rid="table3">Table 3</xref> and <xref ref-type="fig" rid="fig5">Figure 5b</xref>). <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> presents all model fits and DIC scores.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The relationship between human cysticercosis antigen (Ag)-seroprevalence and human age (in years) for each dataset.</title><p>Infection acquisition (simple) or infection acquisition and loss (reversible) catalytic models (<bold>a</bold>) jointly fitted to multiple datasets (single diagnostic sensitivity and specificity values estimated; dataset-specific <italic>λ</italic><sub>inf</sub> and <italic>ρ</italic><sub>inf</sub> estimates obtained) and (<bold>b</bold>) models independently fitted to a single dataset, including 95% confidence intervals associated with observed Ag-seroprevalence point estimates. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the parameter posterior distributions used to construct predicted (all age) seroprevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-fitting model selected by deviance information criterion (DIC); both models presented if difference between DIC &lt; 2 (both models have similar support based on the data); a difference &gt; 10 units indicates that the models are significantly different and therefore only superior fitting model (lowest DIC) is presented. The non-zero predicted seroprevalence at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-seroprevalence data-points are calculated by the Clopper-Pearson exact method.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig5-v1.tif"/></fig><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Antigen seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antigen) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).</title><p>Antigen-based infection acquisition and infection loss rates represent markers of active infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Dataset;Country</th><th align="left" valign="bottom">All-age observed seroprevalence (%) (95% CI)<xref ref-type="table-fn" rid="table3fn2">*</xref></th><th align="left" valign="bottom">Catalytic model</th><th align="left" valign="bottom">Diagnostic sensitivity(95% BCI)</th><th align="left" valign="bottom">Diagnostic specificity(95% BCI)</th><th align="left" valign="bottom"><italic>λ<sub>inf</sub></italic>inf infection acquisition rate, year<sup>–1</sup>(95% BCI)<xref ref-type="table-fn" rid="table3fn3">†</xref></th><th align="left" valign="bottom"><italic>ρ<sub>inf</sub></italic>inf infection loss rate, year<sup>–1</sup>(95% BCI)<xref ref-type="table-fn" rid="table3fn3">†</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="7">Models jointly fitted to multiple datasets (the B158/B60 Ag-ELISA) <sup><xref ref-type="table-fn" rid="table3fn4">‡</xref></sup></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib42">Kanobana et al., 2011</xref>;<break/>DRC</td><td align="left" valign="bottom">21.66<break/>(19.01–24.49)</td><td align="left" valign="bottom" rowspan="5">Reversible <xref ref-type="table-fn" rid="table3fn5">§</xref></td><td align="left" valign="bottom" rowspan="5">0.909<break/>(0.810–0.967)</td><td align="left" valign="bottom" rowspan="5">0.999<break/>(0.995–0.999)</td><td align="left" valign="bottom">0.11<break/>(0.077–0.17)</td><td align="left" valign="bottom">0.330<break/>(0.246–0.464)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>;<break/>Zambia</td><td align="left" valign="bottom">5.79<break/>(4.19–7.77)</td><td align="left" valign="bottom">0.0044<break/>(0.0027–0.0088)</td><td align="left" valign="bottom">0.023<break/>(0.001–0.085)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Sahlu et al., 2019</xref>;<break/>Burkina Faso</td><td align="left" valign="bottom">2.45<break/>(1.93–3.08)</td><td align="left" valign="bottom">0.0016<break/>(0.00091–0.0032)</td><td align="left" valign="bottom">0.029<break/>(0.0016–0.11)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">Conlan et al., 2012</xref>;<break/>Lao PDR</td><td align="left" valign="bottom">2.22<break/>(1.49–3.17)</td><td align="left" valign="bottom">0.0018<break/>(0.00073–0.0034)</td><td align="left" valign="bottom">0.063<break/>(0.0076–0.12)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib57">Nguekam et al., 2003</xref>;<break/>Cameroon</td><td align="left" valign="bottom">0.68<break/>(0.47–0.95)</td><td align="left" valign="bottom">0.00017<break/>(0.000077–0.00030)</td><td align="left" valign="bottom">0.004<break/>(0.00018–0.026)</td></tr><tr><td align="left" valign="bottom" colspan="7">Models independently fitted to a single dataset (the HP10 Ag-ELISA) <sup><xref ref-type="table-fn" rid="table3fn6">¶</xref></sup></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib71">Wardrop et al., 2015</xref>;<break/>Kenya</td><td align="left" valign="bottom">6.61<break/>(5.57–7.76)</td><td align="left" valign="bottom">Simple<sup><xref ref-type="table-fn" rid="table3fn7">**</xref></sup></td><td align="left" valign="bottom">0.850<break/>(0.735–0.927)</td><td align="left" valign="bottom">0.944<break/>(0.930–0.959)</td><td align="left" valign="bottom">0.00054<break/>(0.000053–0.0013)</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom" colspan="7"/></tr></tbody></table><table-wrap-foot><fn><p>NA = Not applicable;.DRC: Democratic Republic of the Congo; PDR: People’s Democratic Republic.</p></fn><fn id="table3fn2"><label>*</label><p>*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.</p></fn><fn id="table3fn3"><label>†</label><p>Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).</p></fn><fn id="table3fn4"><label>‡</label><p>Diagnostic sensitivity and specificity jointly fitted for the B158/B60 Ag-ELISA (<xref ref-type="bibr" rid="bib5">Brandt et al., 1992</xref>; <xref ref-type="bibr" rid="bib18">Dorny et al., 2000</xref>).</p></fn><fn id="table3fn5"><label>§</label><p>Best-fitting model determined by DIC (models jointly fitted to multiple datasets).</p></fn><fn id="table3fn6"><label>¶</label><p>Based on the HP10 Ag-ELISA (<xref ref-type="bibr" rid="bib37">Harrison et al., 1989</xref>).</p></fn><fn id="table3fn7"><label>**</label><p>Best-fitting model determined by DIC (models independently fitted to a single dataset).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Country-wide analysis of human cysticercosis antibody seroprevalence trends in Colombia</title><p>HCC Ab-seroconversion with Ab-seroreversion (reversible model), fitted to multiple datasets using an IgG Ab-ELISA (<xref ref-type="bibr" rid="bib48">López et al., 1988</xref>), provided an improved fit across the 23 (out of a total of 24) departments of Colombia (<xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref>) included in the analysis. <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref> presents parameter estimates from the best-fit reversible model by department (parameter estimates for the simple model fits by department can also be found in <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). <xref ref-type="fig" rid="fig6">Figure 6</xref> presents the best-fit Ab-seroconversion with Ab-seroreversion (reversible) model fit to each age-seroprevalence dataset across departments (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> zooms into model fits in medium to lower all-age seroprevalence departments for improved resolution). One department (Bolívar) was omitted due to difficultly fitting to such a distinct age-seroprevalence profile (prevalence peak in early ages).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The relationship between human cysticercosis antibody (Ab)-seroprevalence and human age (in years) for 23 departments in Colombia.</title><p>Each graph shows observed human cysticercosis Ab age-seroprevalence data (black points) and fitted reversible model (Ab-seroconversion with Ab-seroreversion; best-fitting model). Y-axis units are from 0 to 1 (HCC Ab-seroprevalence), with major y-axis gridlines at 0, 0.2, 0.4, and 0.6 seroprevalence. X-axis units are from 0 to 80 years (human age), with major x-axis gridlines at 0, 20, 40, 60, and 80 years of age.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Human cysticercosis antibody (Ab) age-seroprevalence profiles and (selected by Deviance Information Criterion) model with seroconversion and seroreversion model fits to (<bold>a</bold>) medium all-age Ab-seroprevalence Colombian Departments (6.33–14.37%) and (<bold>b</bold>) low all-age Ab-seroprevalence Colombian Departments (0.48–4.92%).</title><p>For (<bold>a</bold>) and (<bold>b</bold>), Departments are arranged in order of highest to lowest overall Department Ab-seroprevalence. Note the different y-axis scale for (a) medium all-age Ab-seroprevalence Departments (0–0.3) and (b) low all-age Ab-seroprevalence Departments (0–0.15).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Human cysticercosis antibody serosurvey sample size by department in Colombia.</title><p>Blue departments are those included in the model fitting for this chapter. Bolivar* was not included in the model fitting (hence the Department is coloured in grey) - a full assessment is provided in the Results/Discussion of the main text regarding the exclusion of Bolivar. Data from <xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref> and the Instituto National de Salud (INS).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Colombia (<bold>a</bold>) age- antibody (Ab) seroprevalence profile stratified by sex for each department (to determine whether profiles clearly differ by sex) and compared to (<bold>b</bold>) age- Ab-seroprevalence (non-sex stratified) profiles for all 24 departments.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig6-figsupp3-v1.tif"/></fig></fig-group><p><xref ref-type="fig" rid="fig7">Figure 7</xref> highlights the geographical variation in a HCC Ab-seroconversion or FoI, (<bold>b</bold>) HCC Ab-seroreversion rate and c the HCC antibody all-age seroprevalence, across the 23 departments. In addition, <xref ref-type="fig" rid="fig7">Figure 7</xref> presents substantial geographical variation in risk factors, including: (d) the proportion of individuals owning pigs, and (e) the proportion of individuals reporting open defecation practices by department (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> highlights variation in the proportion of pigs being kept under free-ranging management practices and the proportion of pigs being kept under free-ranging/mixed practices in those owning pigs (n=3157)).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Geographic variation in, (<bold>a</bold>) HCC antibody (Ab)<italic>-</italic>seroconversion rate (<italic>λ</italic><sub>sero</sub> or FoI), and (<bold>b</bold>) HCC Ab<italic>-</italic>seroreversion rate (<italic>ρ</italic><sub>sero</sub>), (<bold>c</bold>) human cysticercosis Ab all-age seroprevalence data, (<bold>d</bold>) pig ownership proportion and (<bold>e</bold>) open defecation reported proportion by department.</title><p>The FoI (<italic>λ</italic><sub>sero</sub>) and Ab<italic>-</italic>seroreversion (<italic>ρ</italic><sub>sero</sub>) rates are parameter estimates obtained from the best-fit model with HCC Ab<italic>-</italic>seroconversion and Ab<italic>-</italic>seroreversion (reversible model). Note that San Andrés department is not clearly shown because of its size (small islands located in the top-left of a-c maps). For context, an all-age HCC Ab<italic>-</italic>seroprevalence=0.126, HCC Ab<italic>-</italic>seroconversion rate (FoI or <italic>λ</italic><sub>sero</sub>)=0.023 year-1, and HCC <italic>Ab-</italic>seroreversion rate (<italic>ρ</italic><sub>sero</sub>)=0.19 year-1 was obtained in San Andrés.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Geographic variation in, (<bold>a</bold>) proportion of pigs which free-roam as a management strategy and (<bold>b</bold>) proportion of pigs which free roam or are held in mixed systems as a management strategy.</title><p>These proportions are for a subset of the total dataset, only analysing those owning pigs (n=3,157).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig7-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Force-of-infection across settings</title><p>A more intuitive approach to understanding the FoI (<italic>λ</italic>) is to consider its reciprocal, which here corresponds to the average time until humans become Ab-seropositive (1/<italic>λ<sub>sero</sub></italic>) or infected (1/<italic>λ<sub>inf</sub></italic>) as inferred through Ag-seropositivity. Equally, the reciprocal of <italic>ρ</italic> relates to the average duration that humans remain Ab-seropositive (1/<italic>ρ<sub>sero</sub></italic>) or infected (1/<italic>ρ<sub>inf</sub></italic>). Given the large number of estimates obtained for HCC, parameter estimates from best-fit models were compared across settings (by all-age (sero)prevalence of each dataset and by country). <xref ref-type="fig" rid="fig8">Figure 8</xref> shows an overall decline in the average time (in years) until humans become HCC Ab-seropositive or infected with increasing all-age HCC (sero)prevalence, noting 18 studies identified in endemic settings (0.48–5.71% all-age HCC (sero)prevalence), and 19 estimates in hyperendemic settings (6.33–38.68% all-age HCC seroprevalence). Within countries, there was significant variation in times until humans become HCC Ab-seropositive or infected (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1a</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>The relationship between (<bold>a</bold>) the average time until humans become cysticercosis antibody (Ab)-seropositive or infected (1/<italic>λ</italic>) and overall (all-age) seroprevalence, and (<bold>b</bold>) the average time humans remain cysticercosis Ab seropositive or infected (1/<italic>ρ</italic>) and overall (all-age) seroprevalence.</title><p>The plot is stratified by proposed endemicity levels defined as endemic (&gt;0% and&lt;6% all-age HCC seroprevalence), and hyperendemic (≥6% all-age HCC seroprevalence).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Country-specific estimates of (<bold>a</bold>) the average time (in years) until humans become cysticercosis antibody (Ab)-seropositive or infected (1/<italic>λ</italic>, vertical axis), and (<bold>b</bold>) the average time (in years) humans remain HCC Ab-seropositive or infected (1/<italic>ρ</italic>, vertical axis).</title><p>Marker colour denotes: red = Ab-seroprevalence; blue = antigen seroprevalence. Solid diamonds denote the use of the reversible catalytic model; circles are for the simple (Ab-seroconversion-only) model. Error bars are 95% Bayesian Credible Intervals around estimates. Colombia department error-bars are translucid to improve visibility of median estimates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig8-figsupp1-v1.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>Trends in <italic>ρ</italic> for increasing force-of-infection (FoI; <italic>λ</italic>) estimates for antigen-based estimates (<bold>a</bold>) and antibody (Ab)-based estimates (<bold>b</bold>), and trends in the infection loss (<italic>ρ</italic><sub>inf</sub>) to infection acquisition (<italic>λ</italic><sub>inf</sub>) rates by increasing prevalence for antigen-based estimates (<bold>c</bold>) and trends in Ab-seroreversion (<italic>ρ</italic><sub>sero</sub>) to Ab-seroconversion (<italic>λ</italic><sub>sero</sub>) rates by increasing Ab-seroprevalence for Ab-based estimates (<bold>d</bold>).</title><p>The bottom panels show whether the magnitude in difference between <italic>ρ: λ</italic> with increasing (sero)prevalence (as a proxy for transmission intensity).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig8-figsupp2-v1.tif"/></fig></fig-group><p><xref ref-type="fig" rid="fig8">Figure 8b</xref> presents strong evidence for similar average durations of remaining Ab-seropositive (1/<italic>ρ<sub>sero</sub></italic>) across different endemicity settings and countries (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1b</xref>). However, there was evidence for a trend of decreasing duration of humans remaining infected (1/<italic>ρ<sub>inf</sub></italic>) with increasing all-age prevalence (antigen-based studies; n=5). <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref> shows the relationship between Ab-seroconversion and Ab-seroreversion rates, and the relationship between infection acquisition rates and infection loss rates.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This paper presents the first global FoI estimates for <italic>T. solium</italic> HTT and HCC, identifying geographical heterogeneity that supports calls to implement both locally-adapted control efforts (<xref ref-type="bibr" rid="bib41">Johansen et al., 2017</xref><xref ref-type="bibr" rid="bib25">Gabriël et al., 2017</xref>), and setting-specific parameterisations of <italic>T. solium</italic> transmission models to support such efforts (<xref ref-type="bibr" rid="bib14">Dixon et al., 2019</xref>). We have also placed our HTT FoI estimates in the context of (putative) endemic or hyperendemic settings, with 0.44 per 1,000 people per year for a (single) endemic setting, and from 9.6 to 21 per 1000 per year for two hyperendemic settings. HCC FoI estimates ranged from 0.086 to 21 per 1000 per year in (18, including Colombian departments) endemic settings (0.086–21 for Ab-based surveys; 0.17–4.4 for Ag-based surveys), and from 0.54 to 120 per 1000 per year in (19) hyperendemic settings (2.3–120 for Ab-based surveys; 0.54–110 for Ag-based surveys). Further work will be required to refine the proposed (and preliminary) characterisation of endemicity levels, perhaps linked to severity/morbidity as in other NTDs (<xref ref-type="bibr" rid="bib62">Prost et al., 1979</xref>; <xref ref-type="bibr" rid="bib66">Smith et al., 2013</xref>). This will be relevant to inform what constitutes a hyperendemic setting in need of intensified control interventions, as proposed in the WHO 2021–2030 goals for <italic>T. solium</italic> (<xref ref-type="bibr" rid="bib38">Havelaar et al., 2015</xref>; <xref ref-type="bibr" rid="bib75">World Health Organization, 2020</xref>). Our work also follows the five principles distilled by <xref ref-type="bibr" rid="bib3">Behrend et al., 2020</xref> for communicating policy-relevant NTD modelling to stakeholders and implementation partners (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><p>Across epidemiological settings, there was a clear trend of decreasing average time until humans become HCC Ab-seropositive or infected as inferred through Ag-seropositivity (the reciprocal of <italic>λ<sub>sero</sub> or λ<sub>inf</sub></italic>) with increasing all-age seroprevalence. This makes intuitive sense as the FoI increases in settings with more intense transmission (reflected by a higher all-age seroprevalence). It was not possible to discern whether such trends exist for HTT given the limited availability of HTT datasets with age-stratified prevalence data. Infection loss with infection acquisition was indicated for two HTT copro-Ag-ELISA-based surveys, and five of six HCC antigen-based surveys, supporting inclusion of parameters representing recovery from HTT and HCC in <italic>T. solium</italic> transmission models (<xref ref-type="bibr" rid="bib14">Dixon et al., 2019</xref>). Our infection loss rates for HTT indicate that the duration of adult tapeworm infection (the reciprocal of <italic>ρ<sub>inf</sub></italic>) ranges from 1.3 to 1.4 years (with uncertainty bounds from 1.0 to 2.8 years), aligning with literature estimates suggesting that adult tapeworms live for less than 5 years (<xref ref-type="bibr" rid="bib30">Garcia et al., 2014</xref>), although our values are only based on two studies. In addition, reinfection of individuals with the adult tapeworm is also likely to occur, particularly in high-endemicity settings; therefore, the persistence of antibodies against the adult worm is likely to complicate the measurement of reinfection rates (where antibody seroconversion is equated to infection, although we take care to differentiate between these two processes when interpreting the λ<italic><sub>sero</sub></italic> and λ<italic><sub>inf</sub></italic> parameters). However, with the limited number of HTT-based surveys available to estimate antibody seroconversion and duration of antibody parameters, it is difficult to determine to what extent this is an issue. Understanding antibody kinetics in relation to spontaneous death and elimination of the adult tapeworm (either naturally or following treatment) is therefore an important area for further consideration, especially towards understanding whether seroreversion rates are related to baseline antibody levels. HCC Ab-seroreversion rates (or infection loss rates) from this analysis are also consistently larger than HCC Ab-seroconversion rates (or infection acquisition rates), in agreement with comparisons of HCC Ab-seroreversion to Ab-seroconversion (or Ag-seroreversion to Ag-seroconversion) estimates in the literature, which are generally based on cumulative seroconversion and seroreversion proportions, or rule-based modelling approaches (<xref ref-type="bibr" rid="bib11">Dermauw et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Garcia et al., 2001</xref>; <xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Mwape et al., 2013</xref>).</p><p>Some of the modelled estimates presented here indicate large differences between FoI and Ab-seroreversion/infection loss rates. These differences are particularly evident in datasets, such as Brazil (<xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>) and Risaralda Department in Colombia (<xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref>), where the reversible model was selected for flat age-(sero)prevalence profiles in low (sero)prevalence settings, where the seroreversion parameter provided minimal information with large uncertainty. The flat age-(sero)prevalence in these settings may also be likely explained by false-positives generated given the slightly sub-optimal performance of the serological antibody diagnostic used e.g. posterior median specificity estimates of 98% in Brazil (<xref ref-type="bibr" rid="bib31">Gomes et al., 2002</xref>) for the antibody LLGP-EITB test (<xref ref-type="bibr" rid="bib70">Tsang et al., 1989</xref>), highlighting issues with imperfect specificity of diagnostics in settings with very low transmission intensity.</p><p>The high cysticercosis Ab-seroreversion rates indicated across datasets are likely indicative of substantial transient responses generated from exposure without establishment of infection. This may also explain the high all-age Ab-seroprevalence estimates observed in field studies (<xref ref-type="bibr" rid="bib28">Garcia et al., 2001</xref>). Even with Ag-based surveys, a marker of infection rather than exposure, Ag-positivity may still indicate some degree of transient responses due to partial establishment of (immature) cysts or establishment followed by rapid degeneration of (mature) cysts (<xref ref-type="bibr" rid="bib53">Mwape et al., 2012</xref>). One expectation was that Ab-seroreversion and infection loss rates are fundamentally biological processes so would be fairly consistent across settings. Since Ab-seroreversion or infection loss parameters were allowed to vary among settings, the consistency of the posterior estimates for these parameters indicates that rates of HCC Ab-seroreversion are stable (i.e. no relationship between all-age Ab-seroprevalence and the average duration humans remain Ab-seropositive, <xref ref-type="fig" rid="fig8">Figure 8b</xref>; no relationship between the Ab-seroconversion and Ab-seroreversion rates, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>), confirming this a priori expectation. The average duration humans remain infected (i.e., the reciprocal of the HCC infection loss rate), however, decreases with increasing seroprevalence (and a positive relationship between infection acquisition rates and infection loss rates, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>). Such a signal seen for Ag-based estimates, albeit with only 5 observations, may indicate increased transient responses in higher transmission settings due to more partial establishment of infection. There is however an absence of wider literature to support the hypothesis of exposure intensity affecting probability of successful parasite establishment, but such (transmission intensity-dependent) parasite establishment processed have been incorporated into transmission models for other NTDs (<xref ref-type="bibr" rid="bib35">Hamley et al., 2019</xref>), highlighting an area of future research with implications for control efforts. In the case of Ab-seroreversion rates, where more data are available compared to infection loss rates, it may be suitable in future work to jointly fit the <italic>ρ<sub>sero</sub></italic> parameter for reversible models across settings.</p><p>This analysis also provides, for the first time, a detailed country-level analysis, focused on Colombia, exploring the geographical variation of key epidemiological metrics (FoI and antibody seroreversion) alongside understanding potential drivers of these trends, using a rich dataset generated by <xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref>. Our results identify substantial subnational variation in HCC FoI (measured by Ab-seroconversion) and Ab-seroreversion rates. There appears to be only a limited relationship between these epidemiological quantities, Ab-seroprevalence and other risk factors, including open defecation and pig ownership at the department level, highlighting the complex nature of exposure drivers for HCC. For example, the southeastern rural departments of Vaupés and Amazonas show the highest all-age seroprevalence and FoI estimates. But while Vaupés has one of the highest reported proportions of open defecation, pig ownership is low in both departments. Notwithstanding, substantial subnational variation indicates the need for tailored subnational approaches to control. Spatial variation has been explored formally for this dataset by including spatial structure (i.e. spatial correlation in seropositivity estimated up to approximately 140 km at the Municipality level) into a risk factor analysis, and identifying hot spots of unexplained residual clustering in northern and southern municipalities in Colombia (<xref ref-type="bibr" rid="bib26">Galipó et al., 2021</xref>). The findings from this study further supports the requirement for designing subnational and targeted interventions (risk groups such as those with low education levels and displaced persons), alongside the need to understand epidemiological dynamics at the subnational level.</p><p>A potential limitation of this study is the assumption that diagnostic sensitivity and specificity for a single diagnostic test do not vary substantially among settings (implied by estimating a single posterior for specificity and sensitivity using data from multiple surveys that used the same diagnostic). In reality, there may be some variation in diagnostic performance between settings, particularly for HTT serological diagnostics. For example, the widely used copro-Ag ELISA for detecting adult tapeworm infection is not species specific (<xref ref-type="bibr" rid="bib56">Ng-Nguyen et al., 2017</xref>). Literature estimates indicate high specificity of HCC diagnostics; however, a proportion of positive results by both HCC Ag- and Ab- diagnostics may be due to transient responses and cross-reactions following exposure to the eggs of other other helminths including <italic>Taenia saginata, Echinoccous granulosus</italic> and <italic>Schistosomia species</italic> (<xref ref-type="bibr" rid="bib47">Lightowlers et al., 2016b</xref>; <xref ref-type="bibr" rid="bib58">Noh et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Kojic and White, 2003</xref>; <xref ref-type="bibr" rid="bib24">Furrows et al., 2006</xref>). Limited information exists on the co-distribution and prevalence of potentially cross-reactive <italic>Taenia</italic> species (such as <italic>Taenia saginata</italic>) and other helminths to determine the relative contribution of within- and between-location variability in the performance of specific diagnostic tests.</p><p>The prevailing (and most parsimonious) assumption governing the behaviour of the catalytic models fitted in this analysis is of a constant FoI with respect to age. Collated age-(sero)prevalence profiles presented here largely reveal increasing (sero)prevalence with age, or saturation with age through Ab-seroreversion/infection loss, but this behaviour can also be observed with age-dependent infection rates (<xref ref-type="bibr" rid="bib33">Grenfell and Anderson, 1985</xref>). However, the available data limit the testing of more complex FoI functions. A few datasets appeared indeed to deviate from the basic assumption, for example for HTT dynamics in the DRC (<xref ref-type="bibr" rid="bib49">Madinga et al., 2017</xref>) and Bolívar in Colombia (<xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref>). While it was not possible to fit the current formulation of catalytic models to these datasets, the specific age-prevalence peaks in younger ages may indicate other drivers such as heterogeneity in exposure (by age) or age-related immunity mechanisms. The observations of HTT copro-Ag-ELISA age-prevalence peaks/odds of infection in children from Peru, Guatemala and Zambia (<xref ref-type="bibr" rid="bib20">Falcon et al., 2003</xref>; <xref ref-type="bibr" rid="bib2">Allan et al., 1996</xref>; <xref ref-type="bibr" rid="bib55">Mwape et al., 2015</xref>) suggest that these trends might be more widespread. Age peaks in HTT prevalence could indicate the need for targeted mass drug administration (MDA) programmes, such as delivery of anthelminthics (praziquantel) to school-age children, an approach that could be integrated into existing schistosomiasis control programmes where HTT and schistosomiasis are co-endemic. Should more age-prevalence data become available, especially for HTT, fitting models with age-varying FoI may become relevant as indicated in other NTDs (<xref ref-type="bibr" rid="bib27">Gambhir et al., 2009</xref>).</p><p>The results presented here, particularly for HCC, where many datasets were available, suggest marked geographical heterogeneity in FoI and associated all-age (sero)prevalence estimates. This indicates substantial variation in the intensity of <italic>T. solium</italic> transmission among endemic settings. There is strong evidence for both HCC Ab-seroreversion and infection loss, likely due to transient dynamics which highlights the need for careful interpretation of cross-sectional (sero)prevalence survey estimates. Catalytic models provide useful tools for interpreting such data, which are far more abundant than a few longitudinal surveys reported in the literature. We also quantify, for the first time, the presence of substantial subnational variation in exposure to HCC, highlighting the need for tailored, sub-national control strategies. More work is also required to understand whether age-prevalence peaks (as observed for HTT) are more commonplace, and whether age-targeted control strategies may be required under specific epidemiological and socioeconomic conditions.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Identifying relevant literature, data sources and data extraction</title><p>Published articles with HTT and HCC age-(sero)prevalence <italic>or</italic> age-infection data suitable for constructing age-stratified profiles were identified through two routes. Firstly, by extracting eligible studies from a systematic review of <italic>T. solium</italic> HTT and HCC (sero)prevalence global ranges (<xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref>), and secondly, by updating the <xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref> review, using the same strategy (see Appendix 1), for the period 01/11/2014 to 02/10/2019.</p></sec><sec id="s4-2"><title>Sub-national dataset for Colombia</title><p><xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref> conducted a country-level survey of HCC antibody seroprevalence across 24 of Colombia’s 32 administrative departments, sampling 29,360 individuals. Permission was granted from <italic>Instituto National de Salud</italic> to analyse these data to construct age-seroprevalence profiles. The study collected human cysticercosis Ab-seroprevalence data in the period 2008–2010,, alongside risk-factor data using a three-stage clustered random sampling framework. To maintain suitable sample sizes for model fitting, age-seroprevalence profiles were constructed at the department level (n=850–1291; <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>), rather than at municipality level (n=40–1140). Age-seroprevalence profiles stratified by sex in each department revealed no clear differences (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>), therefore age-seroprevalence data were not stratified by sex for further analysis (but see <xref ref-type="bibr" rid="bib26">Galipó et al., 2021</xref>). Due to difficulty fitting the specific catalytic models to data from the department of Bolívar, only 23 of 24 departments were assessed (n=28,100).</p></sec><sec id="s4-3"><title>Force-of-infection modelling for human taeniasis and human cysticercosis</title><p>The FoI, which describes the average (per capita) rate at which susceptible individuals seroconvert (become Ab-positive) or become infected, was estimated for HTT and HCC for each dataset. Simple and reversible catalytic models (<xref ref-type="fig" rid="fig2">Figure 2</xref>), originally proposed for fitting to epidemiological data by <xref ref-type="bibr" rid="bib52">Muench, 1934</xref>, were fitted to HTT and HCC age-(sero)prevalence profiles. Model parameters fitted to Ab-datasets were interpreted as Ab-seroconversion (<italic>λ<sub>sero</sub></italic>) and Ab-seroreversion (<italic>ρ<sub>sero</sub></italic>) rates, while (copro-) Ag-datasets were interpreted as infection acquisition (<italic>λ<sub>inf</sub></italic>) and infection loss (<italic>ρ<sub>inf</sub></italic>) rates (<xref ref-type="fig" rid="fig2">Figure 2</xref> provides further details of model structure and parameter interpretation). Like the FoI, the infection loss/ seroreversion parameter (<italic>ρ</italic>) was also permitted to vary across settings (<xref ref-type="bibr" rid="bib11">Dermauw et al., 2018</xref>). These two model configurations represent fundamentally different processes (i.e. presence or absence of Ab-seroreversion or infection loss). Therefore, it was the intention of this analysis to explore which of these processes best captures available age-(sero)prevalence data across different epidemiological settings, given the current knowledge gaps in the literature. In particular, there is minimal knowledge relating to how long taeniasis and cysticercosis infections and seropositivity persist in human hosts, on average (estimated here by the reciprocal of infection loss and Ab-seroreversion rates). This enabled us to consider the possibility that transmission intensity drives the presence and extent of infection loss and Ab-seroreversion rates (due to transient antigen responses and/or partial parasite establishment, as explored in the Discussion).</p><p>The true prevalence <italic>p</italic>(<italic>a</italic>) at age <italic>a</italic> is given for the simple model by,<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mtext> </mml:mtext><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula><disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mi>λ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mtext> </mml:mtext><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><list list-type="simple"><list-item><p>and for the reversible model by,</p></list-item></list></sec><sec id="s4-4"><title>Model fitting and comparison</title><p>Analyses were performed in (<xref ref-type="bibr" rid="bib63">R Development Core Team, 2021</xref>), following <xref ref-type="bibr" rid="bib15">Dixon et al., 2020</xref>. A likelihood was constructed assuming that the observed data (representing a binary presence/absence of markers related to exposure or infection) are a realization of an underlying binomial distribution with probability p(a), given by the catalytic model, and adjusted to give the observed prevalence, p’(a), by the sensitivity (se) and specificity (sp) of the diagnostic adopted in the respective datasets (<xref ref-type="bibr" rid="bib13">Diggle, 2011</xref>),<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mrow><mml:msup><mml:mi>p</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Therefore, the likelihood of the data on the number of observed Ab-seropositive or infected humans of age a, r(a), from n(a) humans is,<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">L</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">r</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">Π</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msup><mml:mi mathvariant="normal">p</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi mathvariant="normal">p</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mi mathvariant="normal">r</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where θ denotes, generically, the catalytic model (i.e. FoI, seroreversion/infection loss) and diagnostic performance (i.e. sensitivity and specificity) parameters. When the same diagnostic was used across surveys, sensitivity and specificity were assumed to be the same among surveys, yielding a single posterior distribution for the diagnostic performance (sensitivity, specificity) for each test (whilst retaining dataset-specific estimates of <italic>λ</italic> and <italic>ρ</italic>). The approach captures uncertainty in diagnostic sensitivity and specificity, but does not permit variation in performance across settings.</p><p>A Bayesian Markov chain Monte Carlo (MCMC) Metropolis–Hastings sampling algorithm was implemented to estimate the parameter posterior distribution f(θ|r, n), assuming uniform prior distributions for λ and ρ (<xref ref-type="table" rid="table4">Table 4</xref>). A weakly informative prior for λ, assuming a lognormal distribution (mean informed by the median estimate from the simple model fit, and a standard deviation of 1), was used for reversible model fits to prevent λ chains drifting to flat posterior space and failing to converge.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Range for force-of-infection (FoI), <italic>λ</italic>, and seroreversion / infection loss, <italic>ρ</italic>, uniform priors.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">T.<italic>T. solium</italic> indicator</th><th align="left" valign="bottom"><italic>λ</italic>: limits on uniform prior (year<sup>–1</sup>)</th><th align="left" valign="bottom"><italic>ρ</italic>: limits on uniform prior (year<sup>–1</sup>)</th><th align="left" valign="bottom">Rationale</th></tr></thead><tbody><tr><td align="left" valign="bottom">HTT (copro-antigen (Ag) and antibody (Ab))</td><td align="left" valign="bottom">Minimum: 0<break/>Maximum: 12</td><td align="left" valign="bottom">Minimum: 0.333<break/>Maximum: 1</td><td align="left" valign="bottom"><italic>λ</italic>: maximum seroconversion rate of 12 year<sup>–1</sup>=1 month<sup>–1</sup> (1/<italic>λ</italic>), representing the lower limit before humans become copro-Ag positive (i.e., infected) or Ab-seropositive of 1 month<break/><italic>ρ</italic>: minimum Ab-seroreversion or infection loss rate of 0.333 year<sup>–1</sup>=0.0277 month<sup>–1</sup>, or 36 month duration (1/<italic>ρ</italic>) for humans to remain copro-Ag (i.e. infected) or Ab- seropositive, reflecting the upper average limit assumed for the life- expectancy of adult <italic>Taenia solium</italic> of 3 years (<xref ref-type="bibr" rid="bib32">Gonzalez and Rosenheck, 2002</xref>); a maximum of 0.0833 month<sup>–1</sup> represents the minimum time humans remain copro-Ag (i.e., infected) or Ab-seropositive reflecting the minimum life-expectancy of the adult worm of 12 months (<xref ref-type="bibr" rid="bib29">García et al., 2003</xref>) (1/ <italic>ρ</italic>)</td></tr><tr><td align="left" valign="bottom">HCC (antigen and antibody)</td><td align="left" valign="bottom">Minimum: 0<break/>Maximum: 12</td><td align="left" valign="bottom">Minimum: 0<break/>Maximum: 12</td><td align="left" valign="bottom">Both <italic>λ</italic> and <italic>ρ</italic>: maximum infection acquisition/loss or Ab-seroconversion / Ab-seroreversion rate of 12 year<sup>–1</sup>=1 month<sup>–1</sup> represents the lower limit before humans acquire infection or become Ab-seropositive (1/<italic>λ</italic>), or remain HCC antigen (i.e., infected) or Ab-seropositivity (1/<italic>ρ</italic>) of 1 month.</td></tr></tbody></table><table-wrap-foot><fn><p>N.B. The reciprocal of the rates of λ and ρ give the duration of susceptibility (1/λ; 1/λsero for Ab-based, or 1/λinf for Ag-based) or of remaining infected or Ab-seropositive (1/ρ; 1/ρsero for Ab-based, or 1/ρinf for Ag-based). HTT: human taeniasis; Ab: antibody; Ag: antigen; HCC: human cysticercosis.</p></fn></table-wrap-foot></table-wrap><p>Informative beta distribution priors for the diagnostic sensitivity and specificity were defined to capture literature estimates of the mean and 95%CIs for these parameters; <xref ref-type="fig" rid="fig9">Figure 9</xref> and <xref ref-type="fig" rid="fig10">Figure 10</xref> with <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, provide more detail.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Informative beta distribution priors constructed for sensitivity and specificity parameters for each human taeniasis diagnostic.</title><p><italic>β</italic> prior distributions for: (<bold>a</bold>) sensitivity (se) (left-hand column plots); (<bold>b</bold>) specificity (sp) (right-hand column plots) of each diagnostic, constructed with <italic>α</italic> and <italic>β</italic> shape parameters provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The <italic>β</italic> distribution provides a more flexible alternative to the uniform distribution, where the parameters of interest are constrained between 0 and 1. The shape parameters were chosen based on the literature estimates of se and sp (whereby <italic>α</italic>/(<italic>α+β</italic>)) equals the mean of the distribution (<xref ref-type="bibr" rid="bib44">Lambert, 2018</xref>), and adapted where required to ensure that the spread of the prior distribution included the 95% confidence intervals identified in the literature. Ag: antigen; ELISA: enzyme-linked immunosorbent assay; Ab: antibody; EITB: enzyme-linked immunoelectrotransfer blot.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig9-v1.tif"/></fig><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Informative beta distribution priors constructed for sensitivity and specificity parameters for each human cysticercosis diagnostic.</title><p><italic>β</italic> prior distributions for: (<bold>a</bold>) sensitivity (se) and (<bold>b</bold>) specificity (sp) of each diagnostic, constructed with <italic>α</italic> and <italic>β</italic> shape parameters provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The <italic>β</italic> distribution provides a more flexible alternative to the uniform distribution where the parameters of interest are constrained between 0 and 1 (<xref ref-type="bibr" rid="bib44">Lambert, 2018</xref>). The shape parameters were chosen based on the literature estimates of se and sp (whereby <italic>α</italic>/(<italic>α+β</italic>)) equals the mean of the distribution (<xref ref-type="bibr" rid="bib44">Lambert, 2018</xref>), and adapted where required to ensure that the spread of the prior distribution included the 95% confidence intervals identified in the literature. Ab: antibody; ELISA: enzyme-linked immunosorbent assay; EITB: enzyme-linked immunoelectrotransfer blot; LLGP: lentil lectin-purified glycoprotein; Ig: immunoglobulin; Ag: antigen.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76988-fig10-v1.tif"/></fig><p>A maximum of 20,000,000 iterations were run for models fitted simultaneously to multiple datasets (2,000,000 for models fitted to single datasets) to obtain a sufficient sample to reduce autocorrelation through substantial subsampling, with the first 25% of runs being discarded as burn-in. The parameter posterior distributions, used to generate fitted prevalence curves and associated uncertainties for each model fit, were summarised using the median and 95% Bayesian credible intervals (95% BCIs). Simple and reversible model fits, after being fitted to all datasets, were compared using the deviance information criterion (DIC) (<xref ref-type="bibr" rid="bib67">Spiegelhalter et al., 2002</xref>), with the model yielding the smallest DIC score being selected (<xref ref-type="supplementary-material" rid="supp3 supp4 supp5">Supplementary files 3–5</xref>).</p></sec><sec id="s4-5"><title>Data and code availability</title><p>Code to replicate the analysis is provided at <ext-link ext-link-type="uri" xlink:href="https://github.com/mrc-ide/human_tsol_FoI_modelling">https://github.com/mrc-ide/human_tsol_FoI_modelling</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:fbf523fa5d981757bd3bfa28fd300cd441a7f5a3;origin=https://github.com/mrc-ide/human_tsol_FoI_modelling;visit=swh:1:snp:a6f8798aa43391c38cd3dd78a398179e0f4c1555;anchor=swh:1:rev:b3eb4c05a42a882c13fb755c3e50dfda0f3e4ef3">swh:1:rev:b3eb4c05a42a882c13fb755c3e50dfda0f3e4ef3</ext-link>; <xref ref-type="bibr" rid="bib17">Dixon, 2022</xref>). All age-(sero)prevalence data are available in the following data repository: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.14469/hpc/10047">http://doi.org/10.14469/hpc/10047</ext-link>. Original data for two datasets available (under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License; CC BY 4.0</ext-link>) from the International Livestock Research Institute open-access repository (<ext-link ext-link-type="uri" xlink:href="http://data.ilri.org/portal/dataset/ecozd">http://data.ilri.org/portal/dataset/ecozd</ext-link>) referenced in <xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref> and University of Liverpool open-access repository (<ext-link ext-link-type="uri" xlink:href="http://datacat.liverpool.ac.uk/352/">http://datacat.liverpool.ac.uk/352/</ext-link>) referenced in <xref ref-type="bibr" rid="bib21">Fèvre et al., 2017</xref>.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Summary of studies included in final analysis and the diagnostic parameters used to set the probabilistic constraints for sensitivity and specificity of each test.</title><p><sup>†</sup>Sensitivity and specificity estimated in a Bayesian framework by <xref ref-type="bibr" rid="bib61">Praet et al., 2013</xref>; <sup>††</sup> sensitivity and specificity based on exposure estimated in a Bayesian framework by <xref ref-type="bibr" rid="bib60">Praet et al., 2010</xref>; *limited information on the specific protocol used for the copro-antigen assay; * <xref ref-type="bibr" rid="bib23">Flórez Sánchez et al., 2013</xref> in<italic>dicate that this diagnostic is suitable to determine exposure through detection of anti-cysticercus immunoglobulin G (IgG) antibodies and was evaluated in Colombian patients to assess cross-reactions with different infectious agents (Taenia saginata, Hymenolepis nana, Echinococcus sp., Fasciola hepatica, Entamoeba histolytica, Ascaris lumbricoides, Mansonella ozzardi, Treponema pallidum, Cryptococcus neoformans and HIV)</italic>; ** sensitivity and specificity estimated in a Bayesian framework by <xref ref-type="bibr" rid="bib60">Praet et al., 2010</xref>; <sup>‡</sup> 95%CIs not provided to inform priors, therefore minimal uncertainty introduced around the sensitivity and specificity estimates to construct priors. Original data for two datasets available (under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License; CC BY 4.0</ext-link>) from the <sup>‡‡</sup>International Livestock Research Institute open-access repository (<ext-link ext-link-type="uri" xlink:href="http://data.ilri.org/portal/dataset/ecozd">http://data.ilri.org/portal/dataset/ecozd</ext-link>) referenced in <xref ref-type="bibr" rid="bib39">Holt et al., 2016</xref> and <sup>‡‡‡</sup>University of Liverpool open-access repository (<ext-link ext-link-type="uri" xlink:href="http://datacat.liverpool.ac.uk/352/">http://datacat.liverpool.ac.uk/352/</ext-link>) referenced in <xref ref-type="bibr" rid="bib21">Fèvre et al., 2017</xref>; <sup>ⱡ</sup> sensitivity and specificity estimated in <xref ref-type="bibr" rid="bib22">Fleury et al., 2007</xref>. DRC: Democratic Republic of the Congo; LPDR: Lao People’s Democratic Republic; Ag; antigen; Ab: antibody; ELISA: enzyme-linked immunosorbent assay; LLGP-EITB: Lentil lectin-purified glycoprotein enzyme-linked immunoelectrotransfer blot; Ig: immunoglobulin; km: kilometers, PCC: porcine cysticercosis; RCT: randomized controlled trial.</p></caption><media xlink:href="elife-76988-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Observed prevalence estimates from sub-Saharan Africa, South America, and Asia for studies referring to “hyper-“or “highly-“endemic setting for human taeniasis (HTT) and human cysticercosis (HCC).</title><p>* rES38 Ab-immunblot (<xref ref-type="bibr" rid="bib74">Wilkins et al., 1999</xref>) ** rT24H Ab-ELISA (<xref ref-type="bibr" rid="bib36">Hancock et al., 2006</xref>) <sup>†</sup>B158/B60 Ag-ELISA (<xref ref-type="bibr" rid="bib5">Brandt et al., 1992</xref>; <xref ref-type="bibr" rid="bib18">Dorny et al., 2000</xref>) <sup>††</sup> LLGP-EITB (<xref ref-type="bibr" rid="bib70">Tsang et al., 1989</xref>) <sup>ⱡ</sup>Ab-ELISA confirmed by immunoblot (<xref ref-type="bibr" rid="bib65">Sato et al., 2018</xref>) <sup>ⱡ ⱡ</sup>Copro-PCR (<xref ref-type="bibr" rid="bib65">Sato et al., 2018</xref>). DRC: Democratic Republic of the Congo (DRC); Lao PDR: Lao People’s Democratic Republic.</p></caption><media xlink:href="elife-76988-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>The deviance information criterion (DIC) and parameter estimates for simple and reversible catalytic models fitted to each observed human taeniasis (antibody and antigen) age-seroprevalence dataset (ordered by decreasing value of all-age seroprevalence).</title><p>For diagnostic methods used see the corresponding study in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Seroprevalence results are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method. Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI) and Deviance information criterion (DIC) model fitting scores; * Diagnostic sensitivity and specificity jointly fitted for the Copro-Ag ELISA (<xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref>). <sup>†</sup> Best-fitting model determined by DIC (jointly-fitted dataset). <sup>††</sup> Best-fitting model determined by DIC (individually-fitted dataset). NA = Not applicable; PDR: People’s Democratic Republic.</p></caption><media xlink:href="elife-76988-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>The deviance information criterion (DIC) and parameter estimates for simple and reversible catalytic models fitted to each observed human cysticercosis antibody age-seroprevalence dataset (ordered by decreasing value of all-age seroprevalence).</title><p>For diagnostic methods used see the corresponding study in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Seroprevalence results are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method. Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI) and Deviance information criterion (DIC) model fitting scores; * Diagnostic sensitivity and specificity for the antibody lentil lectin-purified glycoprotein enzyme-linked immunoelectrotransfer blot (Ab LLGP-EITB) assay (<xref ref-type="bibr" rid="bib70">Tsang et al., 1989</xref>) were jointly fitted across datasets. ** Diagnostic sensitivity and specificity for the antibody Ab-ELISA (DiagnosticAutomation/CortezDiagnostic (2006)) assay were jointly fitted across datasets. <sup>†</sup> Best-fitting model determined by DIC (jointly-fitted dataset). <sup>††</sup> Best-fitting model determined by DIC (individually-fitted dataset). NA = Not applicable; PDR: People’s Democratic Republic.</p></caption><media xlink:href="elife-76988-supp4-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>The deviance information criterion (DIC) and parameter estimates for simple and reversible catalytic models fitted to each observed human cysticercosis antigen age-seroprevalence dataset (ordered by decreasing value of all-age seroprevalence).</title><p>For diagnostic methods used see the corresponding study in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Seroprevalence results are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method. Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI) and Deviance information criterion (DIC) model fitting scores; * Diagnostic sensitivity and specificity for the B158/B60 Ag-ELISA (<xref ref-type="bibr" rid="bib5">Brandt et al., 1992</xref>; <xref ref-type="bibr" rid="bib18">Dorny et al., 2000</xref>). <sup>†</sup> Best-fitting model determined by DIC (jointly-fitted dataset). <sup>††</sup> Best-fitting model determined by DIC (individually-fitted dataset). NA = Not applicable; DRC: Democratic Republic of the Congo; PDR: People’s Democratic Republic.</p></caption><media xlink:href="elife-76988-supp5-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>The deviance information criterion (DIC) and parameter estimates for the reversible catalytic model jointly fitted (for diagnostic sensitivity and specificity) to the observed human cysticercosis antibody age-seroprevalence for each available department in Colombia (n=23, ordered by decreasing value of all-age seroprevalence).</title><p>For diagnostic methods used see the corresponding study in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. DIC score for the reversible model was –401.78. Jointly-fitted diagnostic sensitivity was 0.989 (95%BCI: 0.946–0.999) and specificity was 0.998 (95%BCI: 0.993–0.999). Seroprevalence results are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method. Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI) and Deviance information criterion (DIC) model fitting scores.</p></caption><media xlink:href="elife-76988-supp6-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>The deviance information criterion (DIC) and parameter estimates for the simple catalytic model jointly fitted (for diagnostic sensitivity and specificity) to the observed human cysticercosis antibody age-seroprevalence for each available department in Colombia (n=23, ordered by decreasing value of all-age seroprevalence).</title><p>For diagnostic methods used see the corresponding study in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. DIC score for the simple model was –442.7. Jointly-fitted diagnostic sensitivity was 0.987 (95%BCI: 0.966–0.999) and specificity was 0.980 (95%BCI: 0.975–0.984). Seroprevalence results are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method. Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI) and Deviance information criterion (DIC) model fitting scores.</p></caption><media xlink:href="elife-76988-supp7-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>PRIME-NTD (Policy-Relevant Items for Reporting Models in Epidemiology of Neglected Tropical Diseases) Summary.</title><p>Adapted from <xref ref-type="bibr" rid="bib3">Behrend et al., 2020</xref>. Full formulation of the principles:</p><p>Don't do it alone. Engage stakeholders throughout, from the formulation of questions to the discussions on the implications of the findings.</p><p>Reproducibility is key! Prepare and make available (preferably open-source) a complete technical documentation of all model code, mathematical formulas, assumptions and their justification, allowing others to reproduce the model.</p><p>Model calibration, goodness-of-fit and validation are fundamental processes of scientific modelling. All data used should be described in sufficient detail to allow the reader to assess the type and quality of these analyses. When using data by reference, use Principle 2.</p><p>Communicating uncertainty is a hallmark of good modelling practice. Perform a sensitivity analysis of all key parameters, and for each paper reporting model predictions include an uncertainty assessment of those model outputs within the paper.</p><p>Model outcomes should be articulated in the form of testable hypotheses. This allows comparison with other models and future events as part of the ongoing cycle of model improvement. Incorporating prior work by reference in the paper is sufficient. Write what relevant information is contained in the prior work; then note its reference number in the summary table. Please verify that the whole chain of steps in referenced work is actually complete and up-to-date.</p></caption><media xlink:href="elife-76988-supp8-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-76988-transrepform1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All age-(sero)prevalence data are available in the following data repository: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.14469/hpc/10047">http://doi.org/10.14469/hpc/10047</ext-link>. Original data for two datasets available (under the Creative Commons Attribution License; CC BY 4.0) from the International Livestock Research Institute open-access repository (<ext-link ext-link-type="uri" xlink:href="http://data.ilri.org/portal/dataset/ecozd">http://data.ilri.org/portal/dataset/ecozd</ext-link>) referenced in Holt et al. (2016) and University of Liverpool open-access repository (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.17638/datacat.liverpool.ac.uk/352">http://dx.doi.org/10.17638/datacat.liverpool.ac.uk/352</ext-link>) referenced in Fèvre et al. (2017).</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>HR</given-names></name><name><surname>Inthavong</surname><given-names>P</given-names></name><name><surname>Khamlome</surname><given-names>B</given-names></name><name><surname>Blaszak</surname><given-names>K</given-names></name><name><surname>Keokamphe</surname><given-names>C</given-names></name><name><surname>Somoulay</surname><given-names>V</given-names></name><name><surname>Phongmany</surname><given-names>A</given-names></name><name><surname>Burr</surname><given-names>PA</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>B</given-names></name><name><surname>Blacksell</surname><given-names>SD</given-names></name><name><surname>Unger</surname><given-names>F</given-names></name><name><surname>Grace</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Ecosystem approaches to the better management of zoonotic emerging infectious diseases in the Southeast Asia region</data-title><source>ILRI Data Portal</source><pub-id pub-id-type="accession" xlink:href="http://data.ilri.org/portal/dataset/ecozd">ecozd</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Fèvre</surname><given-names>EM</given-names></name><name><surname>de Glanville</surname><given-names>WA</given-names></name><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Cook</surname><given-names>EAJ</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Wamae</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>An integrated study of human and animal infectious disease in the Lake Victoria Crescent small-holder crop-livestock production system, Kenya</data-title><source>DataCat: The Research Data Catalogue</source><pub-id pub-id-type="doi">10.17638/datacat.liverpool.ac.uk/352</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>MAD, PW, CW, ZMC and MGB acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK MRC and the UK Foreign, Commonwealth &amp; Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme supported by the European Union.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>JC</given-names></name><name><surname>Avila</surname><given-names>G</given-names></name><name><surname>Garcia Noval</surname><given-names>J</given-names></name><name><surname>Flisser</surname><given-names>A</given-names></name><name><surname>Craig</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Immunodiagnosis of taeniasis by coproantigen detection</article-title><source>Parasitology</source><volume>101 Pt 3</volume><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1017/s0031182000060686</pub-id><pub-id pub-id-type="pmid">2092303</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>JC</given-names></name><name><surname>Velasquez-Tohom</surname><given-names>M</given-names></name><name><surname>Garcia-Noval</surname><given-names>J</given-names></name><name><surname>Torres-Alvarez</surname><given-names>R</given-names></name><name><surname>Yurrita</surname><given-names>P</given-names></name><name><surname>Fletes</surname><given-names>C</given-names></name><name><surname>de</surname><given-names>MF</given-names></name><name><surname>Alfaro</surname><given-names>H</given-names></name><name><surname>Craig</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Epidemiology of intestinal taeniasis in four, rural</article-title><source>Guatemalan Communities Annals of Tropical Medicine and Parasitology</source><volume>90</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1080/00034983.1996.11813039</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrend</surname><given-names>MR</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name><name><surname>Hamley</surname><given-names>JID</given-names></name><name><surname>Porco</surname><given-names>TC</given-names></name><name><surname>Stolk</surname><given-names>WA</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>de Vlas</surname><given-names>SJ</given-names></name><collab>NTD Modelling Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Modelling for policy: the five principles of the neglected tropical diseases modelling consortium</article-title><source>PLOS Neglected Tropical Diseases</source><volume>14</volume><elocation-id>e0008033</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0008033</pub-id><pub-id pub-id-type="pmid">32271755</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braae</surname><given-names>UC</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Trevisan</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Magnussen</surname><given-names>P</given-names></name><name><surname>Abela-Ridder</surname><given-names>B</given-names></name><name><surname>Ngowi</surname><given-names>H</given-names></name><name><surname>Johansen</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stepwise approach for the control and eventual elimination of taenia solium as a public health problem</article-title><source>BMC Infectious Diseases</source><volume>19</volume><elocation-id>182</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-3812-y</pub-id><pub-id pub-id-type="pmid">30791888</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>JR</given-names></name><name><surname>Geerts</surname><given-names>S</given-names></name><name><surname>De Deken</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Ceulemans</surname><given-names>F</given-names></name><name><surname>Brijs</surname><given-names>L</given-names></name><name><surname>Falla</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in taenia saginata cysticercosis</article-title><source>International Journal for Parasitology</source><volume>22</volume><fpage>471</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/0020-7519(92)90148-e</pub-id><pub-id pub-id-type="pmid">1644522</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlan</surname><given-names>JV</given-names></name><name><surname>Vongxay</surname><given-names>K</given-names></name><name><surname>Khamlome</surname><given-names>B</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Sripa</surname><given-names>B</given-names></name><name><surname>Elliot</surname><given-names>A</given-names></name><name><surname>Blacksell</surname><given-names>SD</given-names></name><name><surname>Fenwick</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>RCA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A cross-sectional study of taenia solium in a multiple taeniid-endemic region reveals competition may be protective</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>87</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2012.11-0106</pub-id><pub-id pub-id-type="pmid">22855759</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coral-Almeida</surname><given-names>M</given-names></name><name><surname>Rodríguez-Hidalgo</surname><given-names>R</given-names></name><name><surname>Celi-Erazo</surname><given-names>M</given-names></name><name><surname>García</surname><given-names>HH</given-names></name><name><surname>Rodríguez</surname><given-names>S</given-names></name><name><surname>Devleesschauwer</surname><given-names>B</given-names></name><name><surname>Benítez-Ortiz</surname><given-names>W</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Incidence of human taenia solium larval infections in an ecuadorian endemic area: implications for disease burden assessment and control</article-title><source>PLOS Neglected Tropical Diseases</source><volume>8</volume><elocation-id>e2887</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002887</pub-id><pub-id pub-id-type="pmid">24852050</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coral-Almeida</surname><given-names>M</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Abatih</surname><given-names>EN</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Benitez</surname><given-names>W</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Taenia solium human cysticercosis: A systematic review of sero-epidemiological data from endemic zones around the world</article-title><source>PLOS Neglected Tropical Diseases</source><volume>9</volume><elocation-id>e0003919</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003919</pub-id><pub-id pub-id-type="pmid">26147942</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>CystiTeam Group for Epidemiology and Modelling of Taenia solium Taeniasis/Cysticercosis</collab></person-group><year iso-8601-date="2019">2019</year><article-title>The world health organization 2030 goals for taenia solium: insights and perspectives from transmission dynamics modelling</article-title><source>Gates Open Research</source><volume>3</volume><elocation-id>1546</elocation-id><pub-id pub-id-type="doi">10.12688/gatesopenres.13068.2</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Coster</surname><given-names>T</given-names></name><name><surname>Van Damme</surname><given-names>I</given-names></name><name><surname>Baauw</surname><given-names>J</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Recent advancements in the control of <italic>taenia solium</italic>: a systematic review</article-title><source>Food and Waterborne Parasitology</source><volume>13</volume><elocation-id>e00030</elocation-id><pub-id pub-id-type="doi">10.1016/j.fawpar.2018.e00030</pub-id><pub-id pub-id-type="pmid">32095601</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dermauw</surname><given-names>V</given-names></name><name><surname>Carabin</surname><given-names>H</given-names></name><name><surname>Ganaba</surname><given-names>R</given-names></name><name><surname>Cissé</surname><given-names>A</given-names></name><name><surname>Tarnagda</surname><given-names>Z</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Millogo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Factors associated with the 18-month cumulative incidence of seroconversion of active infection with <italic>taenia solium</italic> cysticercosis: a cohort study among residents of 60 villages in burkina faso</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>99</volume><fpage>1018</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.18-0294</pub-id><pub-id pub-id-type="pmid">30182917</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="web"><person-group person-group-type="author"><collab>DiagAutom</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Human Cysticercosis IgG (T. Solium) ELISA Test kit</article-title><ext-link ext-link-type="uri" xlink:href="http://www.rapidtest.com/index.php?i=Parasitology-ELISA-kits&amp;id=170&amp;cat=17">http://www.rapidtest.com/index.php?i=Parasitology-ELISA-kits&amp;id=170&amp;cat=17</ext-link><date-in-citation iso-8601-date="2020-03-09">March 9, 2020</date-in-citation></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diggle</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Estimating prevalence using an imperfect test</article-title><source>Epidemiology Research International</source><volume>2011</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1155/2011/608719</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>MA</given-names></name><name><surname>Braae</surname><given-names>UC</given-names></name><name><surname>Winskill</surname><given-names>P</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Devleesschauwer</surname><given-names>B</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Strategies for tackling taenia solium taeniosis/cysticercosis: A systematic review and comparison of transmission models, including an assessment of the wider taeniidae family transmission models</article-title><source>PLOS Neglected Tropical Diseases</source><volume>13</volume><elocation-id>e0007301</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007301</pub-id><pub-id pub-id-type="pmid">30969966</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>MA</given-names></name><name><surname>Winskill</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>WE</given-names></name><name><surname>Whittaker</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>V</given-names></name><name><surname>Sarti</surname><given-names>E</given-names></name><name><surname>Bawm</surname><given-names>S</given-names></name><name><surname>Dione</surname><given-names>MM</given-names></name><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Force-of-infection of taenia solium porcine cysticercosis: a modelling analysis to assess global incidence and prevalence trends</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>17637</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-74007-x</pub-id><pub-id pub-id-type="pmid">33077748</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>MA</given-names></name><name><surname>Winskill</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>WE</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Taenia solium taeniasis/cysticercosis: from parasite biology and immunology to diagnosis and control</article-title><source>Advances in Parasitology</source><volume>112</volume><fpage>133</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/bs.apar.2021.03.003</pub-id><pub-id pub-id-type="pmid">34024358</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Human_tsol_FoI_modelling</data-title><version designator="swh:1:dir:fbf523fa5d981757bd3bfa28fd300cd441a7f5a3">swh:1:dir:fbf523fa5d981757bd3bfa28fd300cd441a7f5a3</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/mrc-ide/human_tsol_FoI_modelling">https://github.com/mrc-ide/human_tsol_FoI_modelling</ext-link></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Vercammen</surname><given-names>F</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Vansteenkiste</surname><given-names>W</given-names></name><name><surname>Berkvens</surname><given-names>D</given-names></name><name><surname>Geerts</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Sero-epidemiological study of taenia saginata cysticercosis in belgian cattle</article-title><source>Veterinary Parasitology</source><volume>88</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/s0304-4017(99)00196-x</pub-id><pub-id pub-id-type="pmid">10681021</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edia-Asuke</surname><given-names>AU</given-names></name><name><surname>Inabo</surname><given-names>HI</given-names></name><name><surname>Mukaratirwa</surname><given-names>S</given-names></name><name><surname>Umoh</surname><given-names>VJ</given-names></name><name><surname>Whong</surname><given-names>CMZ</given-names></name><name><surname>Asuke</surname><given-names>S</given-names></name><name><surname>Ella</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Seroprevalence of human cysticercosis and its associated risk factors among humans in areas of kaduna metropolis, nigeria</article-title><source>Journal of Infection in Developing Countries</source><volume>9</volume><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.3855/jidc.5415</pub-id><pub-id pub-id-type="pmid">26322870</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcon</surname><given-names>N</given-names></name><name><surname>Bernal</surname><given-names>T</given-names></name><name><surname>Lescano</surname><given-names>AG</given-names></name><name><surname>Gavidia</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>García</surname><given-names>HH</given-names></name><name><surname>Tovar</surname><given-names>M</given-names></name><name><surname>Tsang</surname><given-names>VCW</given-names></name><name><surname>Verastegui</surname><given-names>M</given-names></name><name><surname>Moulton</surname><given-names>LH</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>HYPERENDEMIC human and porcine taenia solium infection in perú</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>68</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2003.68.268</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fèvre</surname><given-names>EM</given-names></name><name><surname>de Glanville</surname><given-names>WA</given-names></name><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Cook</surname><given-names>EAJ</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Wamae</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An integrated study of human and animal infectious disease in the lake victoria crescent small-holder crop-livestock production system, kenya</article-title><source>BMC Infectious Diseases</source><volume>17</volume><elocation-id>457</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-017-2559-6</pub-id><pub-id pub-id-type="pmid">28666412</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleury</surname><given-names>A</given-names></name><name><surname>Hernández</surname><given-names>M</given-names></name><name><surname>Avila</surname><given-names>M</given-names></name><name><surname>Cárdenas</surname><given-names>G</given-names></name><name><surname>Bobes</surname><given-names>RJ</given-names></name><name><surname>Huerta</surname><given-names>M</given-names></name><name><surname>Fragoso</surname><given-names>G</given-names></name><name><surname>Uribe-Campero</surname><given-names>L</given-names></name><name><surname>Harrison</surname><given-names>LJS</given-names></name><name><surname>Parkhouse</surname><given-names>RME</given-names></name><name><surname>Sciutto</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis</article-title><source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>78</volume><fpage>970</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2006.107243</pub-id><pub-id pub-id-type="pmid">17337467</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flórez Sánchez</surname><given-names>AC</given-names></name><name><surname>Pastrán</surname><given-names>SM</given-names></name><name><surname>Vargas</surname><given-names>NS</given-names></name><name><surname>Beltrán</surname><given-names>M</given-names></name><name><surname>Enriquez</surname><given-names>Y</given-names></name><name><surname>Peña</surname><given-names>AP</given-names></name><name><surname>Villarreal</surname><given-names>A</given-names></name><name><surname>Salamanca</surname><given-names>L</given-names></name><name><surname>Rincón</surname><given-names>E</given-names></name><name><surname>Garzón</surname><given-names>IP</given-names></name><name><surname>Muñoz</surname><given-names>L</given-names></name><name><surname>Guasmayan</surname><given-names>L</given-names></name><name><surname>Valencia</surname><given-names>C</given-names></name><name><surname>Parra</surname><given-names>S</given-names></name><name><surname>Hernandez</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cisticercosis en colombia estudio de seroprevalencia 2008-2010</article-title><source>Acta Neurológica Colombiana</source><volume>29</volume><fpage>0120</fpage><lpage>8748</lpage></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furrows</surname><given-names>SJ</given-names></name><name><surname>McCroddan</surname><given-names>J</given-names></name><name><surname>Bligh</surname><given-names>WJ</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Lack of specificity of a single positive 50-kda band in the electroimmunotransfer blot (EITB) assay for cysticercosis</article-title><source>Clinical Microbiology and Infection</source><volume>12</volume><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2006.01381.x</pub-id><pub-id pub-id-type="pmid">16643523</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Mwape</surname><given-names>KE</given-names></name><name><surname>Trevisan</surname><given-names>C</given-names></name><name><surname>Braae</surname><given-names>UC</given-names></name><name><surname>Magnussen</surname><given-names>P</given-names></name><name><surname>Thys</surname><given-names>S</given-names></name><name><surname>Bulaya</surname><given-names>C</given-names></name><name><surname>Phiri</surname><given-names>IK</given-names></name><name><surname>Sikasunge</surname><given-names>CS</given-names></name><name><surname>Makungu</surname><given-names>C</given-names></name><name><surname>Afonso</surname><given-names>S</given-names></name><name><surname>Nicolau</surname><given-names>Q</given-names></name><name><surname>Johansen</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Control of taenia solium taeniasis/cysticercosis: the best way forward for sub-saharan africa?</article-title><source>Acta Tropica</source><volume>165</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2016.04.010</pub-id><pub-id pub-id-type="pmid">27140860</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galipó</surname><given-names>E</given-names></name><name><surname>Dixon</surname><given-names>MA</given-names></name><name><surname>Fronterrè</surname><given-names>C</given-names></name><name><surname>Cucunubá</surname><given-names>ZM</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name><name><surname>Stevens</surname><given-names>K</given-names></name><name><surname>Flórez Sánchez</surname><given-names>AC</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spatial distribution and risk factors for human cysticercosis in colombia</article-title><source>Parasites &amp; Vectors</source><volume>14</volume><elocation-id>590</elocation-id><pub-id pub-id-type="doi">10.1186/s13071-021-05092-8</pub-id><pub-id pub-id-type="pmid">34838117</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambhir</surname><given-names>M</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name><name><surname>Burton</surname><given-names>MJ</given-names></name><name><surname>Solomon</surname><given-names>AW</given-names></name><name><surname>Bailey</surname><given-names>RL</given-names></name><name><surname>Holland</surname><given-names>MJ</given-names></name><name><surname>Blake</surname><given-names>IM</given-names></name><name><surname>Donnelly</surname><given-names>CA</given-names></name><name><surname>Jabr</surname><given-names>I</given-names></name><name><surname>Mabey</surname><given-names>DC</given-names></name><name><surname>Grassly</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control</article-title><source>PLOS Neglected Tropical Diseases</source><volume>3</volume><elocation-id>e462</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000462</pub-id><pub-id pub-id-type="pmid">19529762</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Palacios</surname><given-names>LG</given-names></name><name><surname>Jimenez</surname><given-names>I</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Verastegui</surname><given-names>M</given-names></name><name><surname>Wilkins</surname><given-names>P</given-names></name><name><surname>Tsang</surname><given-names>VC</given-names></name><collab>Cysticercosis Working Group in Peru</collab></person-group><year iso-8601-date="2001">2001</year><article-title>Short report: transient antibody response in taenia solium infection in field conditions-a major contributor to high seroprevalence</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>65</volume><fpage>31</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.65.31</pub-id><pub-id pub-id-type="pmid">11504404</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García</surname><given-names>HH</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>Evans</surname><given-names>CAW</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cysticercosis working group in perú</article-title><source>Taenia Solium Cysticercosis Lancet</source><volume>362</volume><fpage>547</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14117-7</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Friedland</surname><given-names>JS</given-names></name><collab>Cysticercosis Working Group in Peru</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Immunology of taenia solium taeniasis and human cysticercosis</article-title><source>Parasite Immunology</source><volume>36</volume><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1111/pim.12126</pub-id><pub-id pub-id-type="pmid">24962350</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>I</given-names></name><name><surname>Veiga</surname><given-names>M</given-names></name><name><surname>Embiruçu</surname><given-names>EK</given-names></name><name><surname>Rabelo</surname><given-names>R</given-names></name><name><surname>Mota</surname><given-names>B</given-names></name><name><surname>Meza-Lucas</surname><given-names>A</given-names></name><name><surname>Tapia-Romero</surname><given-names>R</given-names></name><name><surname>Carrillo-Becerril</surname><given-names>BL</given-names></name><name><surname>Alcántara-Anguiano</surname><given-names>I</given-names></name><name><surname>Correa</surname><given-names>D</given-names></name><name><surname>Melo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Taeniasis and cysticercosis prevalence in a small village from northeastern brazil</article-title><source>Arquivos de Neuro-Psiquiatria</source><volume>60</volume><fpage>219</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1590/S0004-282X2002000200006</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>G</given-names></name><name><surname>Rosenheck</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Outcomes and service use among homeless persons with serious mental illness and substance abuse</article-title><source>Psychiatric Services</source><volume>53</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.53.4.437</pub-id><pub-id pub-id-type="pmid">11919357</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grenfell</surname><given-names>BT</given-names></name><name><surname>Anderson</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>The estimation of age-related rates of infection from case notifications and serological data</article-title><source>The Journal of Hygiene</source><volume>95</volume><fpage>419</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1017/s0022172400062859</pub-id><pub-id pub-id-type="pmid">4067297</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gripper</surname><given-names>LB</given-names></name><name><surname>Welburn</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The causal relationship between neurocysticercosis infection and the development of epilepsy - A systematic review</article-title><source>Infectious Diseases of Poverty</source><volume>6</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s40249-017-0245-y</pub-id><pub-id pub-id-type="pmid">28376856</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamley</surname><given-names>JID</given-names></name><name><surname>Milton</surname><given-names>P</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Basáñez</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, epioncho-ibm: implications for elimination and data needs</article-title><source>PLOS Neglected Tropical Diseases</source><volume>13</volume><elocation-id>e0007557</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007557</pub-id><pub-id pub-id-type="pmid">31805049</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>K</given-names></name><name><surname>Pattabhi</surname><given-names>S</given-names></name><name><surname>Whitfield</surname><given-names>FW</given-names></name><name><surname>Yushak</surname><given-names>ML</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Tsang</surname><given-names>VCW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization and cloning of T24, a taenia solium antigen diagnostic for cysticercosis</article-title><source>Molecular and Biochemical Parasitology</source><volume>147</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.molbiopara.2006.02.004</pub-id><pub-id pub-id-type="pmid">16540186</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>LJ</given-names></name><name><surname>Joshua</surname><given-names>GW</given-names></name><name><surname>Wright</surname><given-names>SH</given-names></name><name><surname>Parkhouse</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Specific detection of circulating surface/secreted glycoproteins of viable cysticerci in taenia saginata cysticercosis</article-title><source>Parasite Immunology</source><volume>11</volume><fpage>351</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.1989.tb00673.x</pub-id><pub-id pub-id-type="pmid">2674862</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havelaar</surname><given-names>AH</given-names></name><name><surname>Kirk</surname><given-names>MD</given-names></name><name><surname>Torgerson</surname><given-names>PR</given-names></name><name><surname>Gibb</surname><given-names>HJ</given-names></name><name><surname>Hald</surname><given-names>T</given-names></name><name><surname>Lake</surname><given-names>RJ</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Bellinger</surname><given-names>DC</given-names></name><name><surname>de Silva</surname><given-names>NR</given-names></name><name><surname>Gargouri</surname><given-names>N</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Cawthorne</surname><given-names>A</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Stein</surname><given-names>C</given-names></name><name><surname>Angulo</surname><given-names>FJ</given-names></name><name><surname>Devleesschauwer</surname><given-names>B</given-names></name><collab>World Health Organization Foodborne Disease Burden Epidemiology Reference Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>World health organization global estimates and regional comparisons of the burden of foodborne disease in 2010</article-title><source>PLOS Medicine</source><volume>12</volume><elocation-id>e1001923</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001923</pub-id><pub-id pub-id-type="pmid">26633896</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>HR</given-names></name><name><surname>Inthavong</surname><given-names>P</given-names></name><name><surname>Khamlome</surname><given-names>B</given-names></name><name><surname>Blaszak</surname><given-names>K</given-names></name><name><surname>Keokamphe</surname><given-names>C</given-names></name><name><surname>Somoulay</surname><given-names>V</given-names></name><name><surname>Phongmany</surname><given-names>A</given-names></name><name><surname>Durr</surname><given-names>PA</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>B</given-names></name><name><surname>Blacksell</surname><given-names>SD</given-names></name><name><surname>Unger</surname><given-names>F</given-names></name><name><surname>Grace</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endemicity of zoonotic diseases in pigs and humans in lowland and upland lao pdr: identification of socio-cultural risk factors</article-title><source>PLOS Neglected Tropical Diseases</source><volume>10</volume><elocation-id>e0003913</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003913</pub-id><pub-id pub-id-type="pmid">27070428</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaraman</surname><given-names>T</given-names></name><name><surname>Prabhakaran</surname><given-names>V</given-names></name><name><surname>Babu</surname><given-names>P</given-names></name><name><surname>Raghava</surname><given-names>MV</given-names></name><name><surname>Rajshekhar</surname><given-names>V</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Muliyil</surname><given-names>J</given-names></name><name><surname>Oommen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Relative seroprevalence of cysticercus antigens and antibodies and antibodies to taenia ova in a population sample in south india suggests immunity against neurocysticercosis</article-title><source>Transactions of the Royal Society of Tropical Medicine and Hygiene</source><volume>105</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2010.10.007</pub-id><pub-id pub-id-type="pmid">21216417</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>MV</given-names></name><name><surname>Trevisan</surname><given-names>C</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Magnussen</surname><given-names>P</given-names></name><name><surname>Braae</surname><given-names>UC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Are we ready for taenia solium cysticercosis elimination in sub-saharan africa?</article-title><source>Parasitology</source><volume>144</volume><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1017/S0031182016000500</pub-id><pub-id pub-id-type="pmid">27094170</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanobana</surname><given-names>K</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Kabwe</surname><given-names>C</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Lukanu</surname><given-names>P</given-names></name><name><surname>Madinga</surname><given-names>J</given-names></name><name><surname>Mitashi</surname><given-names>P</given-names></name><name><surname>Verwijs</surname><given-names>M</given-names></name><name><surname>Lutumba</surname><given-names>P</given-names></name><name><surname>Polman</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>High prevalence of taenia solium cysticerosis in a village community of bas-congo, democratic republic of congo</article-title><source>International Journal for Parasitology</source><volume>41</volume><fpage>1015</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2011.06.004</pub-id><pub-id pub-id-type="pmid">21763695</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojic</surname><given-names>EM</given-names></name><name><surname>White</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A positive enzyme-linked immunoelectrotransfer blot assay result for A patient without evidence of cysticercosis</article-title><source>Clinical Infectious Diseases</source><volume>36</volume><fpage>e7</fpage><lpage>e9</lpage><pub-id pub-id-type="doi">10.1086/344445</pub-id><pub-id pub-id-type="pmid">12491223</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><source>Chapter 8: A Student’s Guide to Bayesian Statistics</source><publisher-loc>London</publisher-loc><publisher-name>SAGE Publications</publisher-name></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lescano</surname><given-names>AG</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Gavidia</surname><given-names>CM</given-names></name><name><surname>Tsang</surname><given-names>VCW</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Moulton</surname><given-names>LH</given-names></name><name><surname>Villaran</surname><given-names>MV</given-names></name><name><surname>Montano</surname><given-names>SM</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Taenia solium cysticercosis hotspots surrounding tapeworm carriers: clustering on human seroprevalence but not on seizures</article-title><source>PLOS Neglected Tropical Diseases</source><volume>3</volume><elocation-id>e371</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000371</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lightowlers</surname><given-names>MW</given-names></name><name><surname>Donadeu</surname><given-names>M</given-names></name><name><surname>Elaiyaraja</surname><given-names>M</given-names></name><name><surname>Maithal</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>KA</given-names></name><name><surname>Gauci</surname><given-names>CG</given-names></name><name><surname>Firestone</surname><given-names>SM</given-names></name><name><surname>Sarasola</surname><given-names>P</given-names></name><name><surname>Rowan</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Anamnestic responses in pigs to the taenia solium TSOL18 vaccine and implications for control strategies</article-title><source>Parasitology</source><volume>143</volume><fpage>416</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1017/S0031182016000202</pub-id><pub-id pub-id-type="pmid">26892239</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lightowlers</surname><given-names>MW</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Gauci</surname><given-names>CG</given-names></name><name><surname>Donadeu</surname><given-names>M</given-names></name><name><surname>Abela-Ridder</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Monitoring the outcomes of interventions against taenia solium: options and suggestions</article-title><source>Parasite Immunology</source><volume>38</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/pim.12291</pub-id><pub-id pub-id-type="pmid">26538513</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López</surname><given-names>M</given-names></name><name><surname>Murillo</surname><given-names>C</given-names></name><name><surname>Sarria</surname><given-names>N</given-names></name><name><surname>Nicholls</surname><given-names>R</given-names></name><name><surname>Corredor</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Estandarización y evaluación de la prueba de ELISA para la detección de anticuerpos en LCR y suero en neurocisticercosis</article-title><source>Acta Neurológica Colombiana</source><volume>4</volume><fpage>164</fpage><lpage>169</lpage></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madinga</surname><given-names>J</given-names></name><name><surname>Kanobana</surname><given-names>K</given-names></name><name><surname>Lukanu</surname><given-names>P</given-names></name><name><surname>Abatih</surname><given-names>E</given-names></name><name><surname>Baloji</surname><given-names>S</given-names></name><name><surname>Linsuke</surname><given-names>S</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Kapinga</surname><given-names>S</given-names></name><name><surname>Polman</surname><given-names>K</given-names></name><name><surname>Lutumba</surname><given-names>P</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>W</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Geospatial and age-related patterns of taenia solium taeniasis in the rural health zone of kimpese, democratic republic of congo</article-title><source>Acta Tropica</source><volume>165</volume><fpage>100</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2016.03.013</pub-id><pub-id pub-id-type="pmid">26996821</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Shamseer</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Ghersi</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Petticrew</surname><given-names>M</given-names></name><name><surname>Shekelle</surname><given-names>P</given-names></name><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Group</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement</article-title><source>Systematic Reviews</source><volume>4</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/2046-4053-4-1</pub-id><pub-id pub-id-type="pmid">25554246</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moro</surname><given-names>PL</given-names></name><name><surname>Lopera</surname><given-names>L</given-names></name><name><surname>Bonifacio</surname><given-names>N</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Silva</surname><given-names>B</given-names></name><name><surname>Verastegui</surname><given-names>M</given-names></name><name><surname>Gonzales</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Cabrera</surname><given-names>L</given-names></name><collab>Cysticercosis Working Group in Peru</collab></person-group><year iso-8601-date="2003">2003</year><article-title>Taenia solium infection in a rural community in the peruvian andes</article-title><source>Annals of Tropical Medicine and Parasitology</source><volume>97</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1179/000349803235002371</pub-id><pub-id pub-id-type="pmid">12831523</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muench</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1934">1934</year><article-title>Derivation of rates from summation data by the catalytic curve</article-title><source>Journal of the American Statistical Association</source><volume>29</volume><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1080/01621459.1934.10502684</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwape</surname><given-names>KE</given-names></name><name><surname>Phiri</surname><given-names>IK</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Muma</surname><given-names>JB</given-names></name><name><surname>Zulu</surname><given-names>G</given-names></name><name><surname>Van den Bossche</surname><given-names>P</given-names></name><name><surname>de Deken</surname><given-names>R</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Taenia solium infections in a rural area of eastern zambia-a community based study</article-title><source>PLOS Neglected Tropical Diseases</source><volume>6</volume><elocation-id>e1594</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001594</pub-id><pub-id pub-id-type="pmid">22479664</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwape</surname><given-names>KE</given-names></name><name><surname>Phiri</surname><given-names>IK</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Muma</surname><given-names>JB</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Flisser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The incidence of human cysticercosis in a rural community of eastern zambia</article-title><source>PLOS Neglected Tropical Diseases</source><volume>7</volume><elocation-id>e2142</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002142</pub-id><pub-id pub-id-type="pmid">23556026</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwape</surname><given-names>KE</given-names></name><name><surname>Phiri</surname><given-names>IK</given-names></name><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Muma</surname><given-names>JB</given-names></name><name><surname>Zulu</surname><given-names>G</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Study and ranking of determinants of taenia solium infections by classification tree models</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>92</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.13-0593</pub-id><pub-id pub-id-type="pmid">25404073</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng-Nguyen</surname><given-names>D</given-names></name><name><surname>Stevenson</surname><given-names>MA</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Vo</surname><given-names>TV</given-names></name><name><surname>Nguyen</surname><given-names>VAT</given-names></name><name><surname>Phan</surname><given-names>TV</given-names></name><name><surname>Hii</surname><given-names>SF</given-names></name><name><surname>Traub</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comparison of a new multiplex real-time PCR with the kato katz thick smear and copro-antigen ELISA for the detection and differentiation of taenia spp: in human stools</article-title><source>PLOS Neglected Tropical Diseases</source><volume>11</volume><elocation-id>e0005743</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005743</pub-id><pub-id pub-id-type="pmid">28686662</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguekam</surname><given-names>JP</given-names></name><name><surname>Zoli</surname><given-names>AP</given-names></name><name><surname>Zogo</surname><given-names>PO</given-names></name><name><surname>Kamga</surname><given-names>ACT</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Losson</surname><given-names>B</given-names></name><name><surname>Geerts</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A seroepidemiological study of human cysticercosis in west cameroon</article-title><source>Tropical Medicine &amp; International Health</source><volume>8</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3156.2003.01000.x</pub-id><pub-id pub-id-type="pmid">12581440</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>YM</given-names></name><name><surname>Handali</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Tsang</surname><given-names>VCW</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Wilkins</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis</article-title><source>Journal of Clinical Microbiology</source><volume>52</volume><fpage>1429</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1128/JCM.03260-13</pub-id><pub-id pub-id-type="pmid">24554747</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>NTD Modelling Consortium Onchocerciasis Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>The world health organization 2030 goals for onchocerciasis: insights and perspectives from mathematical modelling: NTD modelling consortium onchocerciasis group</article-title><source>Gates Open Research</source><volume>3</volume><elocation-id>1545</elocation-id><pub-id pub-id-type="doi">10.12688/gatesopenres.13067.1</pub-id><pub-id pub-id-type="pmid">31723729</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Rodriguez-Hidalgo</surname><given-names>R</given-names></name><name><surname>Speybroeck</surname><given-names>N</given-names></name><name><surname>Ahounou</surname><given-names>S</given-names></name><name><surname>Benitez-Ortiz</surname><given-names>W</given-names></name><name><surname>Berkvens</surname><given-names>D</given-names></name><name><surname>Hul</surname><given-names>AV</given-names></name><name><surname>Barrionuevo-Samaniego</surname><given-names>M</given-names></name><name><surname>Saegerman</surname><given-names>C</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Infection with versus exposure to taenia solium: what do serological test results tell us?</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>83</volume><fpage>413</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2010.10-0121</pub-id><pub-id pub-id-type="pmid">20682891</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praet</surname><given-names>N</given-names></name><name><surname>Verweij</surname><given-names>JJ</given-names></name><name><surname>Mwape</surname><given-names>KE</given-names></name><name><surname>Phiri</surname><given-names>IK</given-names></name><name><surname>Muma</surname><given-names>JB</given-names></name><name><surname>Zulu</surname><given-names>G</given-names></name><name><surname>van Lieshout</surname><given-names>L</given-names></name><name><surname>Rodriguez-Hidalgo</surname><given-names>R</given-names></name><name><surname>Benitez-Ortiz</surname><given-names>W</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bayesian modelling to estimate the test characteristics of coprology, coproantigen ELISA and a novel real-time PCR for the diagnosis of taeniasis</article-title><source>Tropical Medicine &amp; International Health</source><volume>18</volume><fpage>608</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1111/tmi.12089</pub-id><pub-id pub-id-type="pmid">23464616</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prost</surname><given-names>A</given-names></name><name><surname>Hervouet</surname><given-names>JP</given-names></name><name><surname>Thylefors</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Les niveaux d’endémicité dans l’onchocercose</article-title><source>Bulletin of the World Health Organization</source><volume>57</volume><fpage>655</fpage><lpage>662</lpage></element-citation></ref><ref id="bib63"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2021">2021</year><data-title>R: A language and environment for statistical computing</data-title><version designator="4.0.5">4.0.5</version><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org">https://www.R-project.org</ext-link></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahlu</surname><given-names>I</given-names></name><name><surname>Carabin</surname><given-names>H</given-names></name><name><surname>Ganaba</surname><given-names>R</given-names></name><name><surname>Preux</surname><given-names>PM</given-names></name><name><surname>Cissé</surname><given-names>AK</given-names></name><name><surname>Tarnagda</surname><given-names>Z</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Dermauw</surname><given-names>V</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>C</given-names></name><name><surname>Millogo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estimating the association between being seropositive for cysticercosis and the prevalence of epilepsy and severe chronic headaches in 60 villages of rural burkina faso</article-title><source>PLOS Neglected Tropical Diseases</source><volume>13</volume><elocation-id>e0007101</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007101</pub-id><pub-id pub-id-type="pmid">30677038</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>MO</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Yanagida</surname><given-names>T</given-names></name><name><surname>Waikagul</surname><given-names>J</given-names></name><name><surname>Pongvongsa</surname><given-names>T</given-names></name><name><surname>Sako</surname><given-names>Y</given-names></name><name><surname>Sanguankiat</surname><given-names>S</given-names></name><name><surname>Yoonuan</surname><given-names>T</given-names></name><name><surname>Kounnavang</surname><given-names>S</given-names></name><name><surname>Kawai</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Moji</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Taenia solium, taenia saginata, taenia asiatica, their hybrids and other helminthic infections occurring in a neglected tropical diseases’ highly endemic area in lao pdr</article-title><source>PLOS Neglected Tropical Diseases</source><volume>12</volume><elocation-id>e0006260</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006260</pub-id><pub-id pub-id-type="pmid">29420601</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JL</given-names></name><name><surname>Flueckiger</surname><given-names>RM</given-names></name><name><surname>Hooper</surname><given-names>PJ</given-names></name><name><surname>Polack</surname><given-names>S</given-names></name><name><surname>Cromwell</surname><given-names>EA</given-names></name><name><surname>Palmer</surname><given-names>SL</given-names></name><name><surname>Emerson</surname><given-names>PM</given-names></name><name><surname>Mabey</surname><given-names>DCW</given-names></name><name><surname>Solomon</surname><given-names>AW</given-names></name><name><surname>Haddad</surname><given-names>D</given-names></name><name><surname>Brooker</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The geographical distribution and burden of trachoma in africa</article-title><source>PLOS Neglected Tropical Diseases</source><volume>7</volume><elocation-id>e2359</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002359</pub-id><pub-id pub-id-type="pmid">23951378</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Best</surname><given-names>NG</given-names></name><name><surname>Carlin</surname><given-names>BP</given-names></name><name><surname>van der Linde</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Bayesian measures of model complexity and fit</article-title><source>Journal of the Royal Statistical Society</source><volume>64</volume><fpage>583</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1111/1467-9868.00353</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theis</surname><given-names>JH</given-names></name><name><surname>Goldsmith</surname><given-names>RS</given-names></name><name><surname>Flisser</surname><given-names>A</given-names></name><name><surname>Koss</surname><given-names>J</given-names></name><name><surname>Chionino</surname><given-names>C</given-names></name><name><surname>Plancarte</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Detection by immunoblot assay of antibodies to taenia solium cysticerci in sera from residents of rural communities and from epileptic patients in bali</article-title><source>Indonesia The Southeast Asian Journal of Tropical Medicine and Public Health</source><volume>25</volume><elocation-id>7777908</elocation-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Cook</surname><given-names>EAJ</given-names></name><name><surname>Fèvre</surname><given-names>EM</given-names></name><name><surname>Rushton</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Control of taenia solium; A case for public and private sector investment</article-title><source>Frontiers in Veterinary Science</source><volume>6</volume><elocation-id>176</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2019.00176</pub-id><pub-id pub-id-type="pmid">31281823</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>VC</given-names></name><name><surname>Brand</surname><given-names>JA</given-names></name><name><surname>Boyer</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (taenia solium)</article-title><source>The Journal of Infectious Diseases</source><volume>159</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1093/infdis/159.1.50</pub-id><pub-id pub-id-type="pmid">2909643</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardrop</surname><given-names>NA</given-names></name><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Atkinson</surname><given-names>PM</given-names></name><name><surname>de Glanville</surname><given-names>WA</given-names></name><name><surname>Cook</surname><given-names>EAJ</given-names></name><name><surname>Wamae</surname><given-names>CN</given-names></name><name><surname>Gabriël</surname><given-names>S</given-names></name><name><surname>Dorny</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>LJS</given-names></name><name><surname>Fèvre</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The influence of socio-economic, behavioural and environmental factors on taenia spp: transmission in western kenya: evidence from a cross-sectional survey in humans and pigs</article-title><source>PLOS Neglected Tropical Diseases</source><volume>9</volume><elocation-id>e0004223</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004223</pub-id><pub-id pub-id-type="pmid">26641459</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weka</surname><given-names>RP</given-names></name><name><surname>Ikeh</surname><given-names>EI</given-names></name><name><surname>Kamani</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Seroprevalence of antibodies (igg) to taenia solium among pig rearers and associated risk factors in jos metropolis, nigeria</article-title><source>Journal of Infection in Developing Countries</source><volume>7</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.3855/jidc.2309</pub-id><pub-id pub-id-type="pmid">23416651</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welburn</surname><given-names>SC</given-names></name><name><surname>Beange</surname><given-names>I</given-names></name><name><surname>Ducrotoy</surname><given-names>MJ</given-names></name><name><surname>Okello</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The neglected zoonoses--the case for integrated control and advocacy</article-title><source>Clinical Microbiology and Infection</source><volume>21</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2015.04.011</pub-id><pub-id pub-id-type="pmid">25911990</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>PP</given-names></name><name><surname>Allan</surname><given-names>JC</given-names></name><name><surname>Verastegui</surname><given-names>M</given-names></name><name><surname>Acosta</surname><given-names>M</given-names></name><name><surname>Eason</surname><given-names>AG</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name><name><surname>Gonzalez</surname><given-names>AE</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Tsang</surname><given-names>VC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Development of a serologic assay to detect taenia solium taeniasis</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>60</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1999.60.199</pub-id><pub-id pub-id-type="pmid">10072136</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2020">2020</year><source>Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030</source><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>WHO</publisher-name></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Systematic literature search strategy</title><p>Literature searches were conducted for the period 01/11/2014 to 29/01/2019, according to the following outlined in <xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref>:</p><p>In PubMed, using the Boolean operator AND, the terms “cysticercosis” AND “Taenia solium” AND “epidemiology” were introduced in the main search bar and the filters were activated for the period from 1988/12/31 to 2014/10/31.</p><p>In Web of Science, the strategy applied was introducing in the basic search bar the topic “cysticercosis” adding fields with the correspondent Boolean operators: AND Topic = (<italic>Taenia solium</italic>) AND Topic = (epidemiology).</p><p>In the Latin American &amp; Caribbean Health Sciences Literature (LILACS) database, the strategy adopted consisted in introducing in the main search bar the terms “cysticercosis Taenia solium”. In the latter case the term “epidemiology” was excluded to obtain the maximum return of articles since LILACS is a smaller targeted database when compared to PubMed and Web Of Science.</p><p>In addition the literature databases searched in <xref ref-type="bibr" rid="bib8">Coral-Almeida et al., 2015</xref>, the African Journals Online (AJOL) was also searched, with the search strategy terms including “cysticercosis <italic>Taenia solium</italic>”.</p><p>Following identification of article titles, the exclusion criteria at the title and abstract screening stage included: (1) wrong parasite species, (2) non-endemic countries, (3) only pig studies, (4) pre-clinical/clinical research only, (5) diagnostic development only, (6) non-epidemiological study/ primary data not collected, and (7) unrelated topic.</p><p>At the full-text screening stage, the following inclusion criteria were applied: (1) community-based studies with a cross-sectional or longitudinal study design assessing <italic>T. solium</italic> human taeniasis (HTT).</p></sec><sec sec-type="appendix" id="s9"><title>Defining endemicity thresholds</title><p>Observed prevalence estimates from studies mentioning “hyper” or “highly” endemic in the literature are reported in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. We define the threshold between endemic and hyperendemic levels based on the lowest value for human taeniasis prevalence (2.8%, rounded to 3%) and human cysticercosis prevalence (5.8%, rounded to 6%), with studies reporting observed prevalence estimates above this threshold representing hyperendemic settings.</p></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76988.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Marcelo U</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>University of São Paulo</institution></institution-wrap><country>Brazil</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.02.11.22270710" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.11.22270710"/></front-stub><body><p>Dixon and colleagues have collated published &quot;age-prevalence&quot; data from 16 studies (4 from South America, 8 from Africa, and 4 from Asia) to estimate the force of infection of taeniasis/human cysticercosis across diverse endemic settings. This study addresses a major knowledge gap, as little is currently known regarding the extent of current/recent Taenia solium transmission worldwide. The main limitation of this interesting study originates from the very nature of the primary data analyzed. Authors examine how the prevalence of (genus- but not species-specific) antigens shed in the stools or in the plasma and (more or less stage- and species-specific) antibodies changes across age groups and fit simple catalytic models to these very heterogeneous datasets.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76988.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ferreira</surname><given-names>Marcelo U</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>University of São Paulo</institution></institution-wrap><country>Brazil</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ferreira</surname><given-names>Marcelo U</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>University of São Paulo</institution></institution-wrap><country>Brazil</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.11.22270710">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.02.11.22270710v1.full">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Global Force-of-Infection Trends for Human <italic>Taenia solium</italic> Taeniasis/Cysticercosis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Marcelo U Ferreira as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Miles Davenport as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please add a more detailed discussion about the limitations of the dataset analyzed (reviewer #1). Address the potential differences between antigen and antibody detection, the differences between laboratory methods used in each primary study (e.g., species-specificity, sensitivity) and openly discuss how these differences may affect the current analysis.</p><p>2) Please specifically address why the reversible catalytic model has been used to fit some data, while the simple (non-reversible) version has been used to fit other datasets. What is the rationale for using such models with such different assumptions (reviewer #2)?</p><p>3) Please correct the typos listed by reviewers #2 and #3.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Some suggestions are listed below. Given that no new data are to be generated by the authors, I primarily focus on ways of acknowledging the limitations of available data and discussing how can they impact this study.</p><p>1. I would like to see a much more comprehensive discussion on &quot;seroreversion&quot; in human taeniasis and cysticercosis. The basic question is: how quickly antibodies become undetectable after treatment or following spontaneous worm death and elimination? Do seroreversion rates depend on average levels of antibodies at baseline, before treatment (i.e., are individuals heavily exposed to infection within the past few years more likely to remain seropositive long after treatment even in the absence of reinfection)?</p><p>2. If antibodies are not quickly cleared, then seroconversion rates are not synonymous with &quot;infection rates&quot;. In a population with heterogeneous exposure to infection, individuals more frequent exposed to infection may remain seropositive for longer (even if treated) because of memory responses and their antibody status will not change upon reinfection (i.e., they will remain positive). There is a potential bias towards underestimating infection rates from seroconversion data -- especially among individuals who are most likely to be (re)infected..</p><p>3. If the antibody-detection assay used in the Colombian study (described in a local publication, not available to this reviewer) is not strictly species- and stage-specific, and also short-lived (i.e., if only individuals currently exposed to T. solium cysticerci are positive), the age-related prevalence of &quot;cysticercosis&quot; may have been grossly overestimated in this country.</p><p>4. If prevalence data from selected study sites in a dozen countries cannot be taken as representative of the countries/regions of origin, the study is far from being able to estimate &quot;global force-of-infection trends&quot;. Please provide further information regarding the primary studies, in addition to those in Table S1, to help the reader decide whether or not some extrapolation is possible.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Although the work is well written and very organized, I have some concerns about the model and assumptions used in the analysis.</p><p>Equation 3 is different than the one reported by Diggle, 2011. One essential set of parentheses is missing. Please, clarify it.</p><p>The methods section would be improved by presenting the motivations for the models' choice and a brief description of them, including assumptions and limitations. Although the reversible catalytic model (rho&gt;0) is a generalization of the simple form (rho=0), there are two mutually exclusive assumptions: either only conversion or conversion and reversion. Because of it, unless well justified, it seems unlike that a particular pattern of an infectious disease could be described considering two fundamentally different biological processes. As observed in Figures 2, 3 and 4, the data sometimes support the simple model, sometimes support the reversible, and sometimes it is not possible to decide. It means to me that it is not possible to decide between both designs which encapsulates the mechanism driving the disease age-prevalence presented by the data. Please, clarify it.</p><p>Another concern is regarding to the saturation of the reversible model. The current formulation assumes that all individuals are exposed/susceptible to the disease and, therefore, its saturation is controlled by the reversion rate parameter (rho). The greater rho, the lower the saturation. Hypothetically, one can think of a situation in which just a fraction of the population is exposed/susceptible to an underlined disease. In this scenario, the greater the fraction of individuals not exposed/susceptible, the greater the interference bias of the reversion rate. I wonder whether the authors believe that this is a reasonable possibility and, in the affirmative case, please acknowledge the limitation of the methodology.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76988.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please add a more detailed discussion about the limitations of the dataset analyzed (reviewer #1). Address the potential differences between antigen and antibody detection, the differences between laboratory methods used in each primary study (e.g., species-specificity, sensitivity) and openly discuss how these differences may affect the current analysis.</p></disp-quote><p>We thank Reviewer #1 and the Reviewing Editor for providing this feedback. A more detailed response to these points can be found in Author responses 1.3 and 1.8, where we focus on providing clarification on the diagnostic used in Flórez Sánchez <italic>et al.,</italic> (2013). We highlight the difference between inferences made from antibody-based surveys (relating to exposure) and antigen-based surveys (active infection dynamics) in Authors’ responses 1.2 and 1.7.</p><p>We also provide a detailed analysis of the limitations regarding current diagnostics and how these may impact our analysis on lines 411 – 415 regarding imperfect specificity, especially in low (sero)prevalence settings, and on lines 465 – 473 in the Discussion, focussing on implications regarding variation in sensitivity and specificity estimates across settings, as well as the presence of transient responses/ cross-reactions. In particular, our responses on diagnostic test limitations beyond those already mentioned can be found in Authors’ responses 1.1 in relation to taeniasis diagnostics.</p><disp-quote content-type="editor-comment"><p>2) Please specifically address why the reversible catalytic model has been used to fit some data, while the simple (non-reversible) version has been used to fit other datasets. What is the rationale for using such models with such different assumptions (reviewer #2)?</p></disp-quote><p>We thank Reviewer #2 and the Reviewing Editor for providing this feedback. We fitted both models (simple and reversible) to each dataset, to determine whether there is more evidence for biological processes including or excluding seroreversion / infection loss across settings, as this is a key knowledge gap in the field. The best-fit model was then selected and presented. A more detailed response to these points can be found under Authors’ response 2.2.</p><disp-quote content-type="editor-comment"><p>3) Please correct the typos listed by reviewers #2 and #3.</p></disp-quote><p>We thank Reviewers #2 and #3 and the Reviewing Editor for indicating these typographical errors. We will address the specific typos under our responses in the Reviewers #2 and #3 (Public Review and Recommendations) sections.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Some suggestions are listed below. Given that no new data are to be generated by the authors, I primarily focus on ways of acknowledging the limitations of available data and discussing how can they impact this study.</p><p>1. I would like to see a much more comprehensive discussion on &quot;seroreversion&quot; in human taeniasis and cysticercosis. The basic question is: how quickly antibodies become undetectable after treatment or following spontaneous worm death and elimination? Do seroreversion rates depend on average levels of antibodies at baseline, before treatment (i.e., are individuals heavily exposed to infection within the past few years more likely to remain seropositive long after treatment even in the absence of reinfection)?</p></disp-quote><p>We agree with the reviewer that this is an important area for further consideration. There is very limited literature available on the persistence of antibodies raised to the adult tapeworm after spontaneous worm death and elimination, and, as evidenced by the minimal number of available studies with suitable ageprevalence data, we were not able to estimate and assess human taeniasis seroreversion rates in different epidemiological settings. Thus, it is difficult to discuss these dynamics further in our paper at present. We therefore introduce further text to present these considerations as important further research questions that should form part of the T. solium research agenda:</p><p><bold>“</bold>Understanding antibody kinetics in relation to spontaneous death and elimination of the adult tapeworm (either naturally or following treatment) is therefore an important area for further consideration, especially towards understanding whether seroreversion rates are related to baseline antibody levels.” (lines 396 – 399)</p><p>We have also included some further text, as indicated in Authors’ response 1.1, regarding challenges with measuring reinfection rates should antibodies to the adult tapeworm persist long after worm death.</p><p>We currently discuss, in detail, considerations around human cysticercosis (antibody and antigen) seroreversion rates, exploring possible underlying mechanisms to explain the presence/absence and variation in these rates through transient responses and partial establishment of cysts (in the paragraph on lines 416– 440).</p><disp-quote content-type="editor-comment"><p>2. If antibodies are not quickly cleared, then seroconversion rates are not synonymous with &quot;infection rates&quot;. In a population with heterogeneous exposure to infection, individuals more frequent exposed to infection may remain seropositive for longer (even if treated) because of memory responses and their antibody status will not change upon reinfection (i.e., they will remain positive). There is a potential bias towards underestimating infection rates from seroconversion data -- especially among individuals who are most likely to be (re)infected.</p></disp-quote><p>The reviewer raises an important point. We have taken care not to conflate seroconversion rates with infection acquisition rates, relating the former to exposure and the latter to active infection dynamics. We have further clarified in the text that antibody seroconversion refers to exposure and not to active infection in lines 127 – 129, as follows:</p><p>“The FoI parameters of acquisition (λ) and reversion/loss (ρ) (for antibody datasets, a marker of exposure: λ<sub>sero</sub> and ρ<sub>sero</sub>; for antigen datasets, a marker of active infection: λ<sub>inf</sub> and ρ<sub>inf</sub>) were estimated for each dataset.”</p><p>We have also amended the title of Table 1 (see Authors’ response 1.2.), Table 2 and Table 3 to indicate that “Antibody seroconversion and seroreversion rates represent markers of exposure” and “Antigen-based infection acquisition and infection loss rates represent markers of active infection”.</p><disp-quote content-type="editor-comment"><p>3. If the antibody-detection assay used in the Colombian study (described in a local publication, not available to this reviewer) is not strictly species- and stage-specific, and also short-lived (i.e., if only individuals currently exposed to T. solium cysticerci are positive), the age-related prevalence of &quot;cysticercosis&quot; may have been grossly overestimated in this country.</p></disp-quote><p>We thank the reviewer for this question and have detailed in Authors’ responses 1.3 that the López et al., diagnostic used in the Flórez Sánchez et al., 2013 study is indicated as both highly stage- and species-specific (97.6% specific). Therefore, we do not believe that the age-prevalence is overestimated in this study. We agree with the reviewer that this information should be made available in the manuscript, therefore we include more details in the footnote section of Supplementary File 1:</p><p>“** Flórez Sánchez et al., (2013) indicate that this diagnostic is suitable to determine exposure through detection of anti-cysticercus immunoglobulin G (IgG) antibodies and was evaluated in Colombian patients to assess cross-reactions with different infectious agents (Taenia saginata, Hymenolepis nana, Echinococcus sp., Fasciola hepatica, Entamoeba histolytica, Ascaris lumbricoides, Mansonella ozzardi, Treponema pallidum, Cryptococcus neoformans and HIV)<bold>”.</bold></p><p>For the benefit of the reviewer, we have also managed to locate a reference from 1996 describing the assay, which is downloadable from:</p><p>https://revistabiomedica.org/index.php/biomedica/article/view/903</p><p>Corredor et al., (1996) [Standardization and evaluation of ELISA in dried blood eluates collected on filter paper for the diagnosis of cysticercosis]. Biomedica 16<bold>,</bold> 131–133 (in Spanish).</p><disp-quote content-type="editor-comment"><p>4. If prevalence data from selected study sites in a dozen countries cannot be taken as representative of the countries/regions of origin, the study is far from being able to estimate &quot;global force-of-infection trends&quot;. Please provide further information regarding the primary studies, in addition to those in Table S1, to help the reader decide whether or not some extrapolation is possible.</p></disp-quote><p>We agree and thank the reviewer for this feedback. We have addressed the issue of representativeness of each study (where information is available) under Authors’ response 1.4. In several studies, the authors indicated that the study sites, selected from different areas, were representative of specific socioeconomic factors across a region (e.g., Conlan <italic>et al.,</italic> 2012; Jayaraman <italic>et al.,</italic> 2011). We acknowledge that it was difficult to determine how representative some of the other studies were at country level. Having said that, we strongly contend that our analyses, taken in their entirety, do indicate substantial variation in FoI/seroreversion or infection loss estimates across a range of different epidemiological settings representing the major global endemic areas (e.g., South America, sub-Saharan Africa and Asia). The distribution of study sites is visually presented in Figure S2, which is now Figure 1—figure supplement 1: Geographical distribution of studies with human taeniasis (HTT) and human cysticercosis (HCC) age-(sero) prevalence data included in the final analysis (n = 16) by diagnostic method. For this reason, we believe this study reflects the variation in global trends, and therefore propose modifying the manuscript title as follows:</p><p>“Global variation in Force-of-Infection trends for Human Taenia solium Taeniasis/Cysticercosis”.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Although the work is well written and very organized, I have some concerns about the model and assumptions used in the analysis.</p><p>Equation 3 is different than the one reported by Diggle, 2011. One essential set of parentheses is missing. Please, clarify it.</p></disp-quote><p>We thank the reviewer for spotting this. We have amended equation 3 (line 555-556) as follows:<inline-formula><mml:math id="sa2m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>p</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mtext> </mml:mtext><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mtext> </mml:mtext><mml:mo>−</mml:mo><mml:mtext> </mml:mtext><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mtext> </mml:mtext><mml:mo>−</mml:mo><mml:mtext> </mml:mtext><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></p><disp-quote content-type="editor-comment"><p>The methods section would be improved by presenting the motivations for the models' choice and a brief description of them, including assumptions and limitations. Although the reversible catalytic model (rho&gt;0) is a generalization of the simple form (rho=0), there are two mutually exclusive assumptions: either only conversion or conversion and reversion. Because of it, unless well justified, it seems unlike that a particular pattern of an infectious disease could be described considering two fundamentally different biological processes. As observed in Figures2, 3 and 4, the data sometimes support the simple model, sometimes support the reversible, and sometimes it is not possible to decide. It means to me that it is not possible to decide between both designs which encapsulates the mechanism driving the disease age-prevalence presented by the data. Please, clarify it.</p></disp-quote><p>The comments raised by the reviewer are well received. There is indeed paucity of information and data available in the wider literature to understand (a) whether and where antibody seroreversion occurs; (b) the potential degree of variation in seroreversion rates between settings; (c) how long, on average, taeniasis and cysticercosis persist in humans in different epidemiological settings (estimated in our work by taking the reciprocal of infection loss rates), and (d) whether a lack of infection loss better explains trends in age-(sero)prevalence profiles. These are key knowledge gaps that are not described/explored in detail elsewhere. Our modelling approach, albeit more phenomenological rather than truly mechanistic, provides a start to identify potentially underlying drivers of epidemiological patterns. However, we agree that we should describe better our rationale / motivation to justify the approach taken to investigate two models which include these two different biological processes as follows (lines 537 – 546):</p><p>“These two model configurations represent fundamentally different processes (i.e., presence or absence of Ab-seroreversion or infection loss). Therefore, it was the intention of this analysis to explore which of these processes best captures available age-(sero)prevalence data across different epidemiological settings, given the current knowledge gaps in the literature. In particular, there is minimal knowledge relating to how long taeniasis and cysticercosis infections and seropositivity persist in human hosts, on average (estimated here by the reciprocal of infection loss and Abseroreversion rates). This enabled us to consider the possibility that transmission intensity drives the presence and extent of infection loss and Ab-seroreversion rates (due to transient antigen responses and/or partial parasite establishment, as explored in the Discussion).”</p><p>We then postulate possible explanations for a stronger degree of infection loss rates that relate to a higher proportion of transient antigen responses/partial establishment of infection in higher transmission settings in the Discussion (lines 432 – 440), and the need for further investigation into this area.</p><p>The reviewer is also correct in highlighting that across Figures 2-4 (note now Figures 3-5), there is not always a definitive answer to which biological mechanism prevails in terms of explaining age-prevalence dynamics with the datasets found for this study. This is generally a reflection of fitting these models to diverse, but often limited data sources (for example where there is minimal information particularly in the early and latter part of the curves (the very young or older groups in the population) to adequately capture the age-prevalence saturation dynamics). Flat age-(sero)prevalence profiles in low prevalence settings, not necessarily representing limited data but more a reflection of specific epidemiological conditions, also proved challenging for model fitting with these types of parsimonious models.</p><p>However, some trends emerged, particularly across human cysticercosis age(sero)prevalence profiles, in which the majority (71%) of the studies derived from the general systematic literature search indicated that the model with antibody seroreversion or infection loss (reversible model) was preferable across epidemiological settings. (This is 10 out of 14 studies, excluding the Colombian data, but it was also true for the models fitted to all Colombian departments.) This was a key observation also when models were jointly fitted across multiple datasets (e.g., LLGPEITB antibody assay and B158/B60 Ag-ELISA), therefore providing a strong signal that this mechanism (with antibody seroreversion/infection loss) may be driving the dynamics across the majority of settings.</p><disp-quote content-type="editor-comment"><p>Another concern is regarding to the saturation of the reversible model. The current formulation assumes that all individuals are exposed/susceptible to the disease and, therefore, its saturation is controlled by the reversion rate parameter (rho). The greater rho, the lower the saturation. Hypothetically, one can think of a situation in which just a fraction of the population is exposed/susceptible to an underlined disease. In this scenario, the greater the fraction of individuals not exposed/susceptible, the greater the interference bias of the reversion rate. I wonder whether the authors believe that this is a reasonable possibility and, in the affirmative case, please acknowledge the limitation of the methodology.</p></disp-quote><p>We thank the reviewer for raising this consideration around the behaviour of the reversible model. The catalytic model configurations as presented in this analysis assume an average FoI to which all age groups are subjected. Thus, in terms of potential exposure heterogeneity among individuals or by age, we acknowledge that the current model formulations would not be able to reflect these dynamics. Equally, other heterogeneities in exposure may exist, such as by sex (if for example household roles or occupational practices drive exposure, as the case with other NTDs). Currently there are limited or no data for <italic>T. solium</italic> to indicate how these heterogeneities may underpin dynamics. We discuss in some detail the limitations with the current models in capturing these more complex FoI dynamics, such as age-dependent exposure patterns, in the paragraph (lines 474 – 492) of the Discussion.</p></body></sub-article></article>